Research activity information

• Response to ‘Letter to the Editor: “Lymphocyte‐Monocyte Ratio Predicts Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab: A Multicenter Analysis”’

  Tatsuya Sakane, Toshifumi Tada, Takanori Matsuura

  AIM: To investigate whether lymphocyte-to-monocyte ratio (LMR) can predict outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated with durvalumab plus tremelimumab (Dur/Tre). METHODS: A total of 70 patients with unresectable HCC treated with Dur/Tre were included. Survival and adverse events were analyzed in this cohort. RESULTS: The median progression-free survival (PFS) was 2.8 months (95% confidence interval [CI]: 2.1-8.8) and the median overall survival (OS) was 16.2 months (95% CI: 11.1-not reached [NR]). PFS and OS in the low/high LMR group were 2.3 (95% CI: 1.6-3.8)/3.3 (95% CI: 2.4-6.9) months (p = 0.042) and 11.4 (95% CI: 4.5-NR)/NR (95% CI: 16.2-NR) months (p = 0.001), respectively. The hazard ratio (HR) for PFS in the high LMR group, adjusted for inverse probability weighting (IPW), was 0.556 (95% CI: 0.285-1.084, p = 0.085), and the HR for OS was 0.155 (95% CI: 0.045-0.538, p = 0.003). The distribution of response was 2.9% for complete response, 20.0% for partial response, 28.6% for stable disease, and 37.1% for progressive disease, with no significant difference by LMR. Regarding adverse events, immune-related liver injury of any grade differed significantly among patients with low and high LMR. HR spline curve analysis for OS showed that when LMR ranged from approximately 2.5-4.0, the upper limit of the 95% CI remained at or below 1. CONCLUSIONS: LMR can predict outcomes in patients with unresectable HCC treated with Dur/Tre. An appropriate LMR cutoff for predicting OS ranges from approximately 2.5-4.0.

  Jun. 2026, Hepatology Research, 56(6) (6), 1059 - 1060, English, International magazine

  Scientific journal


• Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

  Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Yoshiko Nakamura, Osamu Yoshida, Kazuya Kariyama, Kazuhiro Nouso, Joji Tani, Asahiro Morishita, Masanori Atsukawa, Norio Itokawa, Tomomi Okubo, Taeang Arai, Koichi Takaguchi, Akemi Tsutsui, Takuya Nagano, Ei Itobayashi, Takashi Nishimura, Shinya Fukunishi, Hirayuki Enomoto, Kunihiko Tsuji, Kazunari Tanaka, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Yuichi Koshiyama, Chikara Ogawa, Takeshi Hatanaka, Yuki Kanayama, Satoru Kakizaki, Kazuhito Kawata, Hidenao Noritake, Atsushi Naganuma, Hisashi Kosaka, Kosuke Matsui, Masaki Kaibori, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Jumpei Okamura, Shohei Komatsu, Takanori Matsuura, Shinichiro Nakamura, Yoshihide Ueda, Soo Ki Kim, Hideko Ohama, Fujimasa Tada, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  BACKGROUND AND AIM: This study evaluated clinical outcomes in patients with hepatocellular carcinoma (HCC) treated with durvalumab plus tremelimumab (Dur/Tre) in routine practice, stratified by whether they fulfilled the eligibility criteria of the phase 3 HIMALAYA trial. METHODS: A total of 412 patients with unresectable HCC receiving Dur/Tre at 30 Japanese institutions were enrolled. Of these, 92 fulfilled the HIMALAYA trial eligibility criteria (HIMALAYA group) and 320 did not (non-HIMALAYA group). RESULTS: Median progression-free survival (PFS) was 5.4 months in the HIMALAYA group and 3.0 months in the non-HIMALAYA group (p = 0.012). Multivariable analysis identified body mass index ≥ 25 kg/m2 (hazard ratio [HR], 0.780; 95% confidence interval [CI], 0.612-0.993; p = 0.044) and portal vein invasion (HR, 1.509; 95% CI, 1.049-2.170; p = 0.027) as independent predictors of PFS. Median overall survival (OS) was 19.4 months in the HIMALAYA group versus 15.4 months in the non-HIMALAYA group (p = 0.014). Multivariable analysis showed Eastern Cooperative Oncology Group performance status ≥ 1 (HR, 1.878; 95% CI, 1.253-2.814; p = 0.002) and albumin-bilirubin grade ≥ 2 (HR, 2.032; 95% CI, 1.319-3.318; p = 0.001) as independent determinants of OS. Any-grade endocrine dysfunction occurred in 13 (14.1%) and 21 (6.6%) patients (p = 0.030), with grade ≥ 3 events in 5 (5.4%) and 2 (0.6%), respectively (p = 0.007). Subgroup analysis suggested that non-HIMALAYA patients with ALBI grade 1 may have OS comparable to the HIMALAYA group. CONCLUSIONS: Patients fulfilling the HIMALAYA trial eligibility criteria and those who did not but had preserved hepatic function demonstrated favorable survival outcomes with Dur/Tre.

  May 2026, Journal of gastroenterology and hepatology, English, International magazine

  Scientific journal


• Spatial Profiling Identified Senescent Cancer-Associated Fibroblasts Localized in the Border Region of Human Pancreatic Ductal Adenocarcinoma.

  Yoshiyuki Harada, Atsuhiro Masuda, Takanori Matsuura, Kenji Nagata, Yoshihide Nanno, Atsushi Masamune, Yuzo Kodama, Eiji Hara, Tomonori Matsumoto

  BACKGROUND & AIMS: Pancreatic ductal adenocarcinoma is a highly aggressive malignancy characterized by a fibroblast-rich tumor microenvironment. Cancer-associated fibroblasts closely interact with tumor cells and play a pivotal role in cancer pathogenesis. Single-cell analyses have identified distinct cancer-associated fibroblast subsets that exert either tumor-promoting or tumor-suppressive effects in pancreatic ductal adenocarcinoma. Senescent cancer-associated fibroblasts have recently been linked to poor prognosis through their senescence-associated secretory phenotype. However, the dynamics of senescent cancer-associated fibroblast induction and their spatial distribution in pancreatic ductal adenocarcinoma remain largely unclear. This study aimed to investigate the heterogeneity and spatial organization of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma, with a specific focus on the induction and localization of senescent cancer-associated fibroblasts. METHODS: We performed immunostaining and spatial transcriptomic analyses covering unbiased regions of tumor architecture to map cancer-associated fibroblast subpopulations and characterize senescent cancer-associated fibroblast induction and localization. RESULTS: Senescent cancer-associated fibroblasts were found to accumulate preferentially at the gross tumor edge, and their abundance was associated with poor patient prognosis. Chemotherapy further promoted senescence in myofibroblastic cancer-associated fibroblasts within the tumor core, resulting in an increased population of senescent cancer-associated fibroblasts. Spatial transcriptomic profiling identified gene signatures specific to senescent cancer-associated fibroblasts and revealed their distinct interactions with neighboring cells. Notably, senescent cancer-associated fibroblasts exhibited enhanced transforming growth factor-β signaling activity and upregulation of downstream genes, such as CCN2 and PLAU, which may contribute to tumor proliferation and invasion. CONCLUSIONS: This study reveals that senescent cancer-associated fibroblasts preferentially localize near the gross tumor edge and could impact tumor progression through their senescence-associated secretory phenotype. These findings highlight the spatial plasticity of pancreatic cancer-associated fibroblasts and underscore the pathological significance of senescent cancer-associated fibroblasts in human pancreatic ductal adenocarcinoma.

  May 2026, Cellular and molecular gastroenterology and hepatology, 20(8) (8), 101808 - 101808, English, International magazine

  Scientific journal


• Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study.

  Kaho Aoe, Toshifumi Tada, Atsushi Hiraoka, Tomomitsu Matono, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Naganuma Atsushi, Hisashi Kosaka, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Takanori Matsuura, Yoshihide Ueda, Soo Ki Kim, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Shinya Fukunishi, Kazunari Tanaka, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Jumpei Okamura, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  BACKGROUND AND AIMS: Atezolizumab plus bevacizumab is administered for unresectable HCC, with bevacizumab dosed by body weight, which may not adequately reflect body composition. This study evaluated the association between body surface area (BSA)-adjusted bevacizumab dosing, expressed as the bevacizumab-BSA index (BBI), and outcomes. APPROACH AND RESULTS: This retrospective study included 1507 patients with unresectable HCC treated with atezolizumab plus bevacizumab at 30 Japanese institutions. BBI was the ratio of actual to standard dose per BSA. Restricted cubic spline analyses identified the optimal BBI range. Outcomes were compared among BBI groups. Spline analysis revealed a nonlinear association between BBI and overall survival (OS), with an optimal BBI range of 106%-121%. Accordingly, the patients were classified into under (n=924), target (n=522), and over (n=61) groups. The median progression-free survival was significantly longer in the target group than in the nontarget group (10.3 vs. 6.5 mo, p <0.001), and the median OS was prolonged (24.9 vs. 19.2 mo, p =0.008). Multivariable analysis demonstrated that the target BBI group was independently associated with improved progression-free survival (HR, 0.807; 95% CI: 0.715-0.910; p <0.001) and OS (HR, 0.850; 95% CI: 0.733-0.985; p =0.031). The objective response rate was significantly higher in the Target group ( p =0.023), while treatment-related adverse event rates were comparable across the BBI groups, with no significant differences in proteinuria, hypertension, or other toxicities. CONCLUSIONS: BSA-adjusted bevacizumab dosing was associated with improved efficacy without increased toxicity in patients with unresectable HCC treated with atezolizumab plus bevacizumab.

  May 2026, Hepatology (Baltimore, Md.), English, International magazine

  Scientific journal


• Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study.

  Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Hironori Tanaka, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Yoshihide Ueda, Soo Ki Kim, Fujimasa Tada, Shinichiro Nakamura, Takanori Matsuura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Jumpei Okamura, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  AIM: Evidence regarding the optimal first-line immune checkpoint inhibitor (ICI) regimen for treating unresectable hepatocellular carcinoma (uHCC) with Child-Pugh class B (CP-B) liver function remains limited. This study compared atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (Dur/Tre group) in real-world settings. METHODS: In this multicenter retrospective study, 211 consecutive patients with uHCC and CP-B liver function who underwent ICI-based therapy as a first-line therapy were analyzed. Treatment responses, survival outcomes, albumin-bilirubin (ALBI) score changes, and adverse events were evaluated. Survival analyses were adjusted using inverse probability weighting (IPW). RESULTS: The median progression-free survival associated with the Atez/Bev and Dur/Tre regimens was 5.0 and 3.5 months, respectively; the median corresponding overall survival was 10.5 and 12.4 months. After IPW adjustment, no significant differences were observed in progression-free or overall survival. The Atez/Bev regimen-associated disease control rate was significantly higher (75.2% vs. 55.0%, p = 0.02). The Dur/Tre regimen, meanwhile, was associated with a significantly higher immune-related adverse event incidence (10.5% vs. 32.7%, p < 0.01) and a greater need for high-dose corticosteroid treatment. In contrast, the Atez/Bev regimen resulted in a progressive decrease in ALBI scores, whereas the Dur/Tre regimen maintained the hepatic functional reserve. CONCLUSIONS: The Atez/Bev and Dur/Tre regimens afforded comparable survival outcomes but differed substantially in safety and effects on the hepatic functional reserve. Given the trade-off between immunotoxicity and liver function preservation, treatment selection for CP-B liver function should be individualized, considering baseline hepatic reserve, tolerability, and anticipated treatment trajectory.

  May 2026, Hepatology research : the official journal of the Japan Society of Hepatology, 56(5) (5), 716 - 724, English, International magazine

  Scientific journal


• Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

  Fujimasa Tada, Atsushi Hiraoka, Hideko Ohama, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Yoshihide Ueda, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Jumpei Okamura, Hideyuki Tamai, Shinichiro Nakamura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Shohei Komatsu, Takumi Fukumoto, Takanori Matsuura, Soo Ki Kim, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  AIM: Atezolizumab plus bevacizumab (Atez/Bev) in unresectable hepatocellular carcinoma (uHCC) is a standard first-line therapy, but bleeding-related adverse events (BL-AEs) remain clinically concerning, particularly in real-world patients with advanced tumors, portal hypertension, or undergoing antithrombotic therapy (ATT). We aimed to evaluate whether ATT increases bleeding risk, identify pretreatment factors associated with BL-AEs, and assess the impact of bleeding on progression-free survival (PFS) and overall survival (OS) in patients with uHCC treated with Atez/Bev. METHODS: This multicenter retrospective study included 981 patients with uHCC treated with Atez/Bev. BL-AEs were identified by clinical assessment, imaging, or endoscopy. Predictors of BL-AEs were analyzed using logistic regression. Survival outcomes were compared by Kaplan-Meier method, with inverse probability weighting (IPW) applied to adjust for baseline imbalances. RESULTS: BL-AEs occurred in 102 patients (10.4%) and led to treatment discontinuation in 2.7% patients. Independent predictors of BL-AEs included advanced tumor burden components, such as Vp ≥ 3 portal vein invasion and extrahepatic metastasis. Neither ATT nor portal hypertension-related factors were associated with bleeding risk. PFS did not differ between groups, whereas OS was significantly shorter in the BL group before IPW adjustment than after IPW adjustment. CONCLUSIONS: During Atez/Bev therapy, BL-AEs were primarily associated with advanced tumor burden rather than with ATT or baseline portal hypertension-related factors. Although BL-AEs were associated with poorer OS, this should be interpreted cautiously, as bleeding may reflect aggressive tumor biology rather than a direct mortality cause. Careful monitoring for bleeding complications may be required in patients with advanced tumor burden receiving Atez/Bev.

  Apr. 2026, Hepatology research : the official journal of the Japan Society of Hepatology, English, International magazine

  Scientific journal


• Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.

  Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Yoshihide Ueda, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Jumpei Okamura, Hideyuki Tamai, Shinichiro Nakamura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Fujimasa Tada, Hideko Ohama, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Shohei Komatsu, Takumi Fukumoto, Takanori Matsuura, Soo Ki Kim, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  BACKGROUND & AIMS: Systemic therapy is the standard care for patients with hepatocellular carcinoma (HCC) and extrahepatic metastases. However, the relative prognostic importance of the intrahepatic tumor burden versus the extent of extrahepatic disease in the era of immune checkpoint inhibitor-based therapy remains unclear. This study aimed to clarify the prognostic impact of intrahepatic tumor burden in patients with metastatic HCC treated with atezolizumab plus bevacizumab (Atez/Bev). METHODS: We conducted a multicenter retrospective study of patients with HCC and extrahepatic metastases who received first-line Atez/Bev therapy. The intrahepatic tumor burden was assessed using established radiologic parameters, including tumor size, number, and vascular invasion, and the patients were stratified according to the intrahepatic disease severity. Overall survival (OS) was defined as the primary endpoint. Survival analyses were carried out using the Kaplan-Meier method and Cox proportional hazards models. RESULTS: Overall, 306 patients were included in the study. During a median follow-up of 13.5 months, the OS differed markedly according to the intrahepatic tumor burden and macrovascular invasion. The median OS was 17.8 months in the mild MVI group, 12.2 months in the severe MVI group, 29.8 months in the UT7 in group, and 15.2 months in the UT7 out group (p < 0.001). In multivariate analysis, the intrahepatic tumor burden remained an independent predictor of OS, whereas the extent and number of extrahepatic metastatic sites were not significantly associated with prognosis. CONCLUSIONS: In metastatic HCC treated with atezolizumab plus bevacizumab, intrahepatic tumor burden was associated with overall survival and may be useful for risk stratification and treatment optimization.

  Apr. 2026, Hepatology research : the official journal of the Japan Society of Hepatology, English, International magazine

  Scientific journal


• Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma.

  Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Takanori Matsuura, Yoshihide Ueda, Soo Ki Kim, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Shinya Fukunishi, Kazunari Tanaka, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Jumpei Okamura, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  INTRODUCTION: Atezolizumab plus bevacizumab (Atez/Bev) was the first immune checkpoint inhibitor regimen approved in 2020 for unresectable hepatocellular carcinoma (uHCC), followed by durvalumab plus tremelimumab (Dur/Tre) in 2023. There is very little data available comparing the efficacy and safety of Atez/Bev with those of Dur/Tre. This study aimed to clarify the therapeutic outcomes and safety of Atez/Bev and Dur/Tre. METHODS: We retrospectively analyzed patients with uHCC (BCLC-B/C and Child-Pugh class A) treated with Atez/Bev (n = 302) or Dur/Tre (n = 129) as first-line systemic therapy across multiple institutions between 2023 and 2025. A retrospective comparison of the treatment outcomes and safety of Atez/Bev and Dur/Tre was conducted. RESULTS: The objective response rate and disease control rate were comparable between the Atez/Bev and Dur/Tre groups (31.8%/71.9% vs. 28.7%/63.6%, p = 0.570/p = 0.110, respectively). Median progression-free survival (PFS) was longer with Atez/Bev (9.1 vs. 5.0 months, p = 0.002), while OS was comparable (25.6 vs. 22.1 months, p = 0.172). Similar results were shown after adjusting with inverse probability weighting (IPW). Grade 5 immune-related adverse events occurred in 0.3% (n = 1, interstitial pneumonia) of the patients receiving Atez/Bev and 0.8% (n = 1, colitis) of those receiving Dur/Tre. In the Cox hazard analysis adjusted with IPW, Dur/Tre demonstrated a favorable trend in OS (hazard ratio [HR] <0.75) in patients with elevated alpha-fetoprotein (AFP) (≥100 ng/mL) (HR 0.72, interaction p = 0.006) or double positive elevation of tumor marker (AFP and des-gamma-carboxy prothrombin [≥100 mAU/mL]) (HR 0.66, interaction p = 0.005). CONCLUSION: Although Atez/Bev was associated with a longer PFS, OS did not differ significantly between Atez/Bev and Dur/Tre. This dissociation between PFS and OS may reflect differences in disease biology, treatment sequencing, and post-progression management rather than intrinsic superiority of either regimen. These findings highlight the importance of individualized treatment selection and careful consideration of tumor characteristics and hepatic reserve when choosing first-line immunotherapy for uHCC.

  Apr. 2026, Liver cancer, English, International magazine

  Scientific journal


• Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.

  Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Takanori Matsuura, Yoshihide Ueda, Soo Ki Kim, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Shinya Fukunishi, Kazunari Tanaka, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Jumpei Okamura, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  BACKGROUND AND AIMS: This multicenter retrospective study in Japan aimed to investigate the prognostic significance of lymphocyte-to-monocyte ratio (LMR) in patients with unresectable hepatocellular carcinoma (HCC) treated with durvalumab plus tremelimumab (Dur/Tre). METHODS: A total of 377 patients with HCC and treated with Dur/Tre across 30 institutions in Japan were included in this multicenter study. Time-dependent receiver operating characteristic (ROC) analysis was performed to determine the optimal LMR cut-off value. Hazard ratio (HR) spline curve analysis was used to identify the optimal LMR range for predicting progression-free survival (PFS) and overall survival (OS). RESULTS: Time-dependent ROC analysis identified an optimal LMR cut-off value of 2.52 for predicting median OS. Multivariate analysis demonstrated that an LMR of ≥ 2.52 was independently associated with superior PFS (HR: 0.777) and OS (HR: 0.657). The median PFS was 2.6 months in patients with an LMR of < 2.52, compared with 3.5 months in those with an LMR of ≥ 2.52 (p = 0.022). The median OS was 12.8 months in patients with an LMR of < 2.52, compared with 23.4 months in those with an LMR of ≥ 2.52 (p < 0.001). The disease control rate was significantly higher in the high LMR group (p = 0.032). The HR spline curve analysis revealed that an LMR range of approximately 1.8-2.6 represents an optimal cut-off for predicting both PFS and OS. CONCLUSIONS: LMR is a readily accessible prognostic biomarker for both PFS and OS in patients with unresectable HCC treated with Dur/Tre, and may serve as a practical tool for risk stratification in clinical practice.

  Apr. 2026, Liver international : official journal of the International Association for the Study of the Liver, 46(4) (4), e70570, English, International magazine

  Scientific journal


• Impact of Borderline Resectable Criteria on Hepatocellular Carcinoma Treatment From the Perspective of Tumor Burden

  Shohei Komatsu, Toshifumi Tada, Nobuaki Ishihara, Masaki Omori, Takanori Matsuura, Eisuke Ueshima, Keitaro Sofue, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Yoshihide Nanno, Hiroaki Yanagimoto, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND: The classification of oncological resectability for hepatocellular carcinoma (HCC) has been established, requiring validation of treatment outcomes for hepatectomy and systemic chemotherapy. METHODS: The study evaluated treatment outcomes in 978 patients who underwent hepatectomy and 222 patients with HCC who received first-line systemic chemotherapy (atezolizumab plus bevacizumab, lenvatinib, or durvalumab plus tremelimumab). RESULTS: Among three factors defining patients with borderline resectable 1 (BR1) and 2 (BR2), macrovascular invasion factor was associated with significantly worse prognosis in a hepatectomy group (BR1: 34.2 vs. 63.4 months, p = 0.04; BR2: 14.4 vs. 20.9 months, p = 0.004). In contrast, in the systemic chemotherapy group, none of the three factors affected prognosis in either BR1 or BR2 patients. In BR2 patients undergoing hepatectomy, those with a single risk factor had significantly better outcomes than those with 2-3 factors (20.1 vs. 12.6 months, p < 0.001). Similarly, in the entire systemic chemotherapy cohort, patients with a single risk factor had better outcomes than those with 2-3 (22.6 vs. 11.9 months, p = 0.001). However, among chemotherapy responders (per modified Response Evaluation Criteria in Solid Tumors), prognosis did not significantly differ between those with one factor and those with 2-3 factors (25.4 vs. 24.5 months, p = 0.502). CONCLUSION: Macrovascular invasion significantly impacted prognosis in patients undergoing hepatectomy, for both BR1 and BR2, whereas any of the tumor factors did not affect the prognosis of patients receiving systemic chemotherapy. Tumor burden correlated with prognosis in the entire cohort but not in chemotherapy responders, suggesting effective treatment may overcome poor prognostic indicators.

  Apr. 2026, World Journal of Surgery, 50(4) (4), 1049 - 1058, English, International magazine

  Scientific journal


• Utility of Oncological Resectability Criteria in Recurrent Hepatocellular Carcinoma After Hepatectomy

  Nobuaki Ishihara, Shohei Komatsu, Toshifumi Tada, Takanori Matsuura, Eisuke Ueshima, Keitaro Sofue, Masaki Omori, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Kentaro Tai, Toshihiko Yoshida, Keisuke Arai, Hiroaki Yanagimoto, Yuzo Kodama, Takamichi Murakami, Takumi Fukumoto

  INTRODUCTION: Recurrent hepatocellular carcinoma (HCC) after hepatectomy remains a major clinical challenge, necessitating effective prognostic stratification. The oncological resectability criteria recently proposed by the Japan Liver Cancer Association and the Japanese Society of Hepato-Biliary-Pancreatic Surgery have not yet been validated in recurrent settings. This study aimed to evaluate the prognostic utility of these criteria in patients with recurrent HCC after hepatectomy. METHODS: This retrospective study included 505 patients with recurrent HCC following initial hepatectomy. Patients were classified into three groups-resectable (R), borderline resectable 1 (BR1), and borderline resectable 2 (BR2)-based on the oncological resectability criteria. Post-recurrence survival was evaluated using the Kaplan-Meier method, and multivariate analysis was performed to identify clinical factors associated with post-recurrence survival. RESULTS: Among the 505 patients, 248 patients were classified as R, 80 as BR1, and 177 as BR2. The median post-recurrence survival was 73.4 months for the R group, 33.6 months for the BR1 group, and 12.4 months for the BR2 group (p < 0.001). Multivariate analysis identified BR1/BR2 classification (p < 0.001), modified albumin-bilirubin grade 2b or 3 (p < 0.001), and recurrence within 1 year (p = 0.004) as independent predictors of poor post-recurrence survival. CONCLUSIONS: The oncological resectability criteria effectively stratified post-recurrence survival in patients with recurrent HCC. These findings suggest that a multidisciplinary approach may benefit patients with BR1 or BR2 recurrence. Further studies are warranted to explore optimal treatment strategies for recurrent HCC.

  Mar. 2026, Hepatology Research, 56(3) (3), 368 - 376, English, International magazine

  Scientific journal


• Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice.

  Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Teruki Miyake, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Takanori Matsuura, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  BACKGROUND: Findings regarding long-term outcomes of unresectable hepatocellular carcinoma (uHCC) patients treated with atezolizumab and bevacizumab (Atez/Bev) have yet to be reported. This study was performed to evaluate results regarding 3 year survival of such patients treated in real-world clinical settings. METHODS: This multicenter retrospective study included 555 patients with Child-Pugh A and BCLC stage B or C, for whom Atez/Bev treatment was initiated in the period from 2020 to 2021. Best treatment response, progression-free survival (PFS), overall survival (OS), post-progression survival (PPS), and immune-related adverse events (irAEs) were analyzed. RESULTS: Median age was 73 years and 80.2% were male. Atez/Bev was given as first-line therapy in 55.3%. Objective response rate (ORR) was 41.3% and disease control rate (DCR) was 79.4%. Median PFS was 6.2 months, while median OS was 21.6 months with a 3 year survival rate of 29.7%. Patients treated with Atez/Bev as first-line therapy showed a higher 3 year survival rate of 35.9%. Post-progression treatment was administered to 54.1% of the patients and median PPS in those was 10.9 months. Conversion therapy was performed in 5.9%. IrAEs occurred in 13.3% (grade 5: 0.7%). CONCLUSIONS: uHCC patients treated with Atez/Bev in clinical practice settings showed good ORR and DCR, as well as favorable long-term survival with a 3 year survival rate of approximately 30%, including 35.9% for first-line users.

  Feb. 2026, Cancer medicine, 15(2) (2), e71640, English, International magazine

  Scientific journal


• Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis.

  Takeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Satoru Kakizaki, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Yuichi Koshiyama, Chikara Ogawa, Hiroki Nishikawa, Takashi Nishimura, Kazuhito Kawata, Hisashi Kosaka, Kosuke Matsui, Atsushi Naganuma, Hironori Tanaka, Hideko Ohama, Hidekatsu Kuroda, Tomomitsu Matono, Tomoko Aoki, Hironori Ochi, Michitaka Imai, Shinichiro Nakamura, Shohei Komatsu, Hideyuki Tamai, Jumpei Okamura, Yuki Kanayama, Kazunari Tanaka, Fujimasa Tada, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takanori Matsuura, Hidenao Noritake, Hirayuki Enomoto, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  AIMS: This study aimed to evaluate the therapeutic efficacy of durvalumab and tremelimumab (Dur/Tre) in patients with hepatocellular carcinoma (HCC) who had a tumor thrombus in the main portal vein trunk (Vp4) or high tumor burden (HTB). METHODS: A total of 309 patients with BCLC stage B or C HCC who received Dur/Tre between March 2023 and October 2024 were included. HTB was defined as the presence of at least one of the following radiological findings: ≥ 50% liver involvement by HCC, bile duct invasion, or the presence of Vp4. RESULTS: Both the patients with Vp4 and HTB-positive group had significantly higher proportions of BCLC stage C disease (p = 0.01 and 0.007, respectively) and serum DCP levels ≥ 100 mAU/mL (p = 0.03 and < 0.001, respectively), and significantly higher neutrophil-to-lymphocyte ratio (p = 0.04 and p = 0.004, respectively) compared to their respective counterparts. While the objective response rate did not significantly differ between the HTB-positive and HTB-negative groups (21.6% vs. 16.2%, p = 0.5), it was significantly higher in patients with Vp4 than in those without (42.9% vs. 15.6%, p = 0.02). There were no significant differences in progression-free survival or overall survival (OS) between patients with and without Vp4 (p = 0.1 and 0.3, respectively) and nor between the HTB-positive and HTB-negative groups (both p = 0.3). Among patients with both Vp4 and HTB, responders had longer OS than non-responders. CONCLUSIONS: Dur/Tre may be a viable treatment option for patients with Vp4 and HTB.

  Jan. 2026, Hepatology research : the official journal of the Japan Society of Hepatology, 56(1) (1), 89 - 99, English, International magazine

  Scientific journal


• EUS-Guided Versus Percutaneous Transhepatic Drainage of Liver Abscesses: A Multicenter Endohepatology Study in Western Japan (EPIC-LA Study).

  Takeshi Ogura, Taira Kuroda, Takanori Matsuura, Jun Kitadai, Koh Kitagawa, Masahiro Itonaga, Kotaro Takeshita, Tomoaki Matsumori, Tomoya Emori, Mamoru Takenaka, Hajime Imai, Koichiro Mandai, Shuhei Shintani, Nao Fujimori, Hideyuki Shiomi, Masanori Asada, Ryota Sagami, Hirotsugu Maruyama, Tsukasa Ikeura, Masaaki Shimatani, Hidefumi Nishikiori, Kazuyuki Matsumoto, Masahito Kokubu, Hideki Kamada, Yusuke Ishida, Akitoshi Hakoda, Masayuki Kitano

  OBJECTIVE: Percutaneous transhepatic liver abscess drainage (PTAD) and endoscopic ultrasound-guided liver abscess drainage (EUS-LAD) have several limitations. Recently, because of technical improvements in echoendoscope maneuvers, EUS-guided access for the right hepatic lobe has been reported. The aim of this multicenter, retrospective study was to compare clinical outcomes of PTAD and EUS-LAD including the right hepatic lobe in West Japan. METHOD: This retrospective, multicenter study included consecutive patients with liver abscesses between January 2019 and November 2024. The primary outcome in this study was the clinical success rate compared between EUS-LAD and PTAD. RESULTS: During the study period, 1012 consecutive patients developed liver abscesses. Of them, 734 patients were excluded, 43 underwent EUS-LAD and 235 patients underwent PTAD. After propensity score-matched analysis, the clinical success rate was significantly higher in the EUS-LAD group (97.7%, 42/43) than in the PTAD group (79.1%, 34/43) (p = 0.007). After a propensity score-matched analysis, 25 patients were included in each group. The clinical success rate was significantly higher in the EUS-LAD group (100%, 25/25) than in the PTAD group (84%, 21/25) (p = 0.037). Adverse events were also significantly higher in the PTAD group (16%, 5/25) than in the EUS-LAD group (p = 0.025). In addition, the median length of hospital stay was significantly shorter in the EUS-LAD group (15 days) than in the PTAD group (22 days) (p = 0.005). CONCLUSIONS: EUS-LAD using a metal stent might be one of the options, but further randomized, controlled trials are needed.

  Jan. 2026, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 38(1) (1), e70067, English, International magazine

  Scientific journal


• Impact of intrahepatic lesions on lesion-specific response rates in patients with hepatocellular carcinoma treated with lenvatinib or immune checkpoint inhibitors.

  Masaki Omori, Shohei Komatsu, Toshifumi Tada, Nobuaki Ishihara, Takanori Matsuura, Eisuke Ueshima, Yoshimi Fujishima, Jun Ishihda, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Keitaro Sofue, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND: This study evaluated how lesion location affects treatment response and prognosis in hepatocellular carcinoma (HCC) patients treated with lenvatinib (LEN) or immune checkpoint inhibitors (ICIs; atezolizumab/bevacizumab or durvalumab/tremelimumab). Considering tumor microenvironment and heterogeneity, we analyzed lesion-specific responses to optimize therapy. METHODS: In this retrospective study, lesion-specific responses were assessed for intrahepatic lesions (IHLs), lung, lymph node, intra-abdominal, and other lesions; bone metastases were excluded due to evaluation limitations. Responses were measured using a modified size-based RECIST 1.1 method. Lesion-specific objective response rate (ORR) and disease control rate (DCR) were compared between LEN and ICI groups. RESULTS: ORR for IHLs was higher with ICIs than LEN (16.3 % vs. 3.5 %, P = 0.002). No significant differences were observed for lung, lymph node, or intra-abdominal lesions; adrenal metastases showed no response in either group. Subgroup analysis indicated better ORR and DCR for lung lesions treated with ICIs and lymph node lesions treated with LEN in patients without IHLs versus those with IHLs. CONCLUSIONS: ICIs achieved higher ORR in IHLs than LEN, with no significant differences for metastatic lesions. The presence of IHLs may influence distant lesion response, and therapeutic efficacy varies with treatment regimen.

  Nov. 2025, HPB : the official journal of the International Hepato Pancreato Biliary Association, 28(2) (2), 209 - 217, English, International magazine

  Scientific journal


• Intermediate stage肝細胞癌に対する当院のAtezolizumab+Bevacizumab併用療法の治療成績と奏効因子の検討

  井上 裕太, 多田 俊史, 新丸 尚輝, 坂根 達哉, 江原 真由実, 河野 未樹, 北代 隼, 松浦 敬憲, 塩見 優紀, 大森 將貴, 小松 昇平, 福本 巧, 児玉 裕三

  (一社)日本肝臓学会, Oct. 2025, 肝臓, 66(Suppl.3) (Suppl.3), A879 - A879, Japanese


• Utilizing the Conversion Concept Based on Disease Status Following Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma

  Shohei Komatsu, Toshifumi Tada, Kazuki Terashima, Nobuaki Ishihara, Masaki Omori, Takanori Matsuura, Eisuke Ueshima, Keitaro Sofue, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND: The introduction of atezolizumab plus bevacizumab (Ate/Bev) has improved hepatocellular carcinoma (HCC) treatment, enabling the concept of "ABC conversion," where curative treatments follow Ate/Bev. However, the optimal post-Ate/Bev treatment strategy remains unclear. METHODS: This study evaluated 149 patients with unresectable HCC treated with Ate/Bev and categorized them into six groups: drug-free, surgery, radiotherapy, transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy (TACE/HAIC), chemotherapy, and best supportive care (BSC). The surgery, radiotherapy, and TACE/HAIC groups were classified as "local conversion" and further subdivided into two subtypes based on the therapeutic intent: "curative local conversion" and "palliative local conversion." RESULTS: The 3-year overall survival (OS) rates for patients in the drug-free, surgery, radiotherapy, TACE/HAIC, chemotherapy, and BSC groups were 100.0%, 66.7%, 52.6%, 41.0%, 13.6%, and 10.1%, respectively (p < 0.001). No significant differences were observed between the surgery and TACE/HAIC groups (3-year OS: 66.7% vs. 41.0% and p = 0.441) or between the radiotherapy and TACE/HAIC groups (3-year OS: 52.6% vs. 41.0% and p = 0.838). Patients who underwent local conversion had a significantly better median survival time (28.0 vs. 16.3 months and p < 0.001). The 3-year OS rates for patients who underwent curative and palliative local conversion were 68.6% and 37.0%, respectively. Although curative local conversion demonstrated better prognosis than that noted with palliative local conversion, the difference was not statistically significant (p = 0.155). CONCLUSION: Local conversion after Ate/Bev treatment may potentially improve survival rates. Even when curative local conversion is not feasible, palliative local conversion may still offer clinical benefits.

  Oct. 2025, World Journal of Surgery, 49(10) (10), 2854 - 2862, English, International magazine

  Scientific journal


• Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma.

  Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Teruki Miyake, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Takanori Matsuura, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  BACKGROUND: Immune-mediated adverse events (imAEs) are a significant concern in patients with unresectable hepatocellular carcinoma (uHCC) undergoing combination immunotherapy with durvalumab and tremelimumab (Dur/Tre). This study aimed to investigate the potential association of risk factors, particularly nutrition and immune markers, associated with the development of imAEs. METHODS: Between November 2022 and December 2024, 312 patients with uHCC treated with Dur/Tre were enrolled and retrospectively analyzed. Clinical characteristics, inflammatory markers, and nutritional indices (Geriatric Nutritional Risk Index [GNRI], body mass index, Prognostic Nutritional Index-Onodera, C-reactive protein-to-albumin ratio, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio) were evaluated to identify predictors for imAE development. RESULTS: The imAEs occurred in 122 patients (39.1%), most commonly affecting dermatological, gastrointestinal, and endocrine systems. On multivariate analysis, only normal GNRI (≥ 98) was independently associated with a higher incidence of imAE (odds ratio: 1.99, 95% confidence interval: 1.05-3.79, P = 0.036). Patients with GNRI ≥ 98 also showed better overall survival (OS) than those with GNRI < 98 (not reached vs. 12.5 months, P < 0.001). Among patients who developed imAEs, no significant differences were observed in the imAE types or high-dose steroid use between the GNRI ≥ 98 group (n = 66) and the GNRI < 98 group (n = 56) (40.9% vs. 58.9%, P = 0.069). CONCLUSIONS: Normal GNRI status (≥ 98) was associated with an increased risk of imAE development and improved OS in patients with uHCC receiving Dur/Tre therapy. GNRI may be a useful clinical factor for identifying patients at higher risk of developing imAEs.

  Aug. 2025, Journal of gastroenterology, 60(11) (11), 1427 - 1436, English, Domestic magazine

  Scientific journal


• Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis.

  Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hidenao Noritake, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takashi Nishimura, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Hideyuki Tamai, Takanori Matsuura, Shohei Komatsu, Yoshihide Ueda, Yoshiko Nakamura, Osamu Yoshida, Kosuke Matsui, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo

  AIM: To evaluate the safety and efficacy of durvalumab plus tremelimumab (Dur/Tre) in older adults with unresectable hepatocellular carcinoma (HCC). METHODS: A total of 345 patients with HCC who received Dur/Tre were included in this study. Using propensity score matching, we compared outcomes between older (aged ≥ 75 years; n = 120) and younger individuals (n = 120). RESULTS: The median progression-free survival (PFS) was 3.3 months in the older group and 4.5 months in the younger group (p = 0.271). The median overall survival (OS) was 17.0 months in older individuals and 19.2 months in younger individuals (p = 0.598). No statistically significant differences were observed in the therapeutic response between the two groups (p = 0.264). Additionally, the incidence of immune-mediated adverse events (AEs) did not differ significantly between older and younger individuals. Multivariate analyses revealed that age group (older vs. younger) was not an independent prognostic factor for PFS (p = 0.250) or OS (p = 0.489). In a subgroup analysis stratifying older individuals into three age categories (75-79, 80-84, and ≥ 85 years), no significant differences were observed in the cumulative OS or PFS across the subgroups (p = 0.308 and 0.783). Similarly, the incidence of immune-mediated AEs did not differ significantly among the age categories. CONCLUSIONS: Dur/Tre appears to be a safe and effective treatment option for patients with HCC, regardless of age. Dur/Tre appears to be a safe and effective treatment option for patients with unresectable HCC, regardless of age.

  Aug. 2025, Hepatology research : the official journal of the Japan Society of Hepatology, 55(11) (11), 1507 - 1517, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab.

  Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takashi Nishimura, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Hideyuki Tamai, Takanori Matsuura, Shohei Komatsu, Yoshihide Ueda, Yoshiko Nakamura, Osamu Yoshida, Kosuke Matsui, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo

  BACKGROUND AND AIMS: To assess the outcomes of patients with hepatocellular carcinoma (HCC) who were treated with atezolizumab plus bevacizumab (Atezo/Bev), categorised by oncological resectability criteria, which reflect tumour burden and extent of disease. METHODS: A cohort of 467 HCC patients who received Atezo/Bev was enrolled. Patients were classified into two groups based on oncological resectability criteria: BR (borderline resectable) 1 (n = 153) and BR2 (n = 314). RESULTS: The median progression-free survival (PFS) was 9.0 months in the BR1 group and 6.8 months in the BR2 group (p = 0.014). Multivariable analysis identified the following independent prognostic factors for PFS: age ≥ 75 years (hazard ratio [HR], 1.309), albumin-bilirubin (ALBI) grade ≥ 2 (HR, 1.494), neutrophil-to-lymphocyte ratio (NLR) ≥ 3 (HR, 1.289), α-fetoprotein ≥ 100 ng/mL (HR, 1.523) and BR2 classification (HR, 1.360). The median overall survival (OS) was 25.3 months in the BR1 group and 22.3 months in the BR2 group (p = 0.048). Multivariable analysis identified the following independent prognostic factors for OS: age ≥ 75 years (HR, 1.522), ALBI grade ≥ 2 (HR, 2.411), NLR ≥ 3 (HR, 1.635), α-fetoprotein ≥ 100 ng/mL (HR, 1.530) and BR2 classification (HR, 1.421). When oncological resectability factors (tumour number and size, vascular invasion and extrahepatic spread) were incorporated into the multivariable analysis, major vascular invasion emerged as a significant predictor of both PFS (HR, 3.188) and OS (HR, 2.650). CONCLUSIONS: In patients with HCC characterised by limited resectability undergoing Atezo/Bev, vascular invasion, in addition to liver function, is a critical prognostic determinant of tumour progression.

  Aug. 2025, Liver international : official journal of the International Association for the Study of the Liver, 45(8) (8), e70217, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Selective identification of polyploid hepatocellular carcinomas with poor prognosis by artificial intelligence-based pathological image recognition

  Takanori Matsuura, Masatoshi Abe, Yoshiyuki Harada, Masahiro Kido, Hajime Nagahara, Yuzo Kodama, Yoshihide Ueda, Eiji Hara, Hirohiko Niioka, Tomonori Matsumoto

  BACKGROUND: Polyploidy is frequently observed in cancer cells and is closely associated with chromosomal instability, which can lead to cancer progression. Polyploid cancers are more aggressive than diploid cancers, and polyploidy has been shown to be a prognostic marker for hepatocellular carcinoma (HCC). However, polyploidy is challenging to diagnose. Currently, no clinically implementable methods are available for diagnosing polyploidy in cancer. METHODS: We established a method for assessing polyploidization in HCC using deep-learning-based artificial intelligence image recognition models to assess hematoxylin and eosin-stained pathological images. Using 44 HCCs whose ploidy status had been determined by chromosome fluorescence in situ hybridization, we evaluated the ability of our constructed deep learning models to detect HCC ploidy. We then tested the models on an independent group of 169 liver cancers and applied them to a publicly available dataset. RESULTS: Here we show that our constructed models effectively assess HCC ploidy in a separate cohort and identify a subset with poor prognosis based on the ploidy determinations for 169 HCCs. Our pipeline also identifies HCCs with poor prognosis in the external dataset, with a more significant difference than that for ploidy inferences by genomic analysis. By exploiting the high processing capacity of artificial intelligence, new aspects of polyploid HCC, such as the high prevalence of scirrhous structures, are identified. CONCLUSIONS: Our findings suggest that ploidy assessment using artificial intelligence-based pathological image recognition can serve as a novel diagnostic tool for personalized medicine.

  Jul. 2025, Communications Medicine, 5(1) (1), 270 - 270, English, International magazine

  Scientific journal


• Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.

  Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takashi Nishimura, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Hideyuki Tamai, Takanori Matsuura, Shohei Komatsu, Yoshihide Ueda, Yoshiko Nakamura, Osamu Yoshida, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo

  AIM: To investigate the prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) on outcomes in patients with hepatocellular carcinoma (HCC) treated with durvalumab plus tremelimumab (Dur/Tre). METHODS: A total of 182 patients with HCC who received Dur/Tre were included in the analysis. Univariate and multivariate survival analyses were conducted. Additionally, hazard ratio (HR) spline curve analysis was used to determine the optimal NLR cut-off values for predicting overall survival (OS). RESULTS: The median progression-free survival (PFS) was 3.5 months (95% confidence interval [CI]: 2.7-4.4), whereas the median OS was not reached (95% CI: 12.1 months-not reached). Multivariate analysis demonstrated that treatment with Dur/Tre as a second-line therapy or beyond was independently associated with worse PFS (HR: 1.819; 95% CI: 1.230-2.688; p = 0.003). Furthermore, an NLR of ≥ 2.56 was identified as an independent predictor of reduced OS (HR: 1.919; 95% CI: 1.033-3.566; p = 0.039). The median OS was not reached (95% CI: 12.3 months-not reached) in patients with an NLR of < 2.56, compared with 12.1 months (95% CI: 9.0 months-not reached) in those with an NLR of ≥ 2.56 (p = 0.016). A Sankey diagram illustrating post-treatment outcomes revealed that a significantly larger proportion of patients with high NLRs did not proceed to subsequent therapies but instead received best supportive care (p = 0.046). Spline curve analysis showed that an NLR range of approximately 2.3-3.0 represents an appropriate cut-off for predicting OS. CONCLUSIONS: The NLR is a significant prognostic biomarker for OS in patients with HCC treated with Dur/Tre.

  Jun. 2025, Hepatology research : the official journal of the Japan Society of Hepatology, 55(9) (9), 1285 - 1295, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Prognosis of Hepatectomy versus Systemic Chemotherapy Based on Oncological Resectability Criteria for Borderline Resectable Hepatocellular Carcinoma.

  Shohei Komatsu, Toshifumi Tada, Takashi Nishimura, Motofumi Tanaka, Atsushi Takebe, Saeko Kushida, Yoshimi Fujishima, Nobuaki Ishihara, Takanori Matsuura, Ikuo Nakamura, Taro Okazaki, Masahiro Tsuda, Jun Ishida, Ippei Matsumoto, Seiko Hirono, Hirayuki Enomoto, Yuzo Kodama, Takumi Fukumoto

  INTRODUCTION: Oncological resectability criteria for hepatocellular carcinoma have been defined (resectable [R]/borderline resectable 1 [BR1]/borderline resectable 2 [BR2]); however, their validation is necessary. METHODS: A total of 1,469 patients who underwent hepatectomy and 525 patients who received systemic chemotherapy, including lenvatinib, atezolizumab plus bevacizumab, and durvalumab plus tremelimumab, as first-line treatment were analyzed. RESULTS: In the BR1 group, the median survival times (MSTs) of patients who underwent hepatectomy and systemic chemotherapy were 52.7 and 34.6 months, respectively, without a significant difference (p = 0.075). In the propensity score matching (PSM) analysis of the BR1 group, the MSTs of hepatectomy and systemic chemotherapy were 42.4 and 35.1 months, respectively, without a significant difference (p = 0.772). Hepatitis virus infection, modified albumin-bilirubin (mALBI) grade 2b + 3, and the presence of extrahepatic metastasis were identified as poor prognostic factors for hepatectomy, whereas mALBI grade 2b + 3 was the only poor prognostic factor for systemic chemotherapy. In the BR2 group, the MSTs of hepatectomy and systemic chemotherapy were 20.1 and 19.5 months, respectively, with significantly better survival for hepatectomy than for systemic chemotherapy (p = 0.017). In the PSM analysis of the BR2 group, the MSTs of hepatectomy and systemic chemotherapy were 20.1 and 21.0 months, respectively, without a significant difference (p = 0.375). Serum alpha-fetoprotein levels≥100, intrahepatic tumor number ≥6, and the presence of extrahepatic metastasis were identified as poor prognostic factors for hepatectomy, whereas female, serum alpha-fetoprotein levels ≥100, mALBI grade 2b + 3, intrahepatic maximal tumor size >5 cm, and the presence of extrahepatic metastasis were identified as poor prognostic factors for systemic chemotherapy. CONCLUSION: In the PSM analysis, no significant differences were observed between the BR1 and BR2 groups for hepatectomy and systemic chemotherapy. The intrahepatic tumor number for hepatectomy and the intrahepatic maximal tumor size for systemic chemotherapy are significant risk factors for BR2 patients, highlighting the characteristics of each treatment and the potential for selecting the optimal modality.

  Jun. 2025, Liver cancer, 15(1) (1), 38 - 49, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Development of a Predictive Model for Classifying Immune Checkpoint Inhibitor-Induced Liver Injury Types.

  Jun Kitadai, Toshifumi Tada, Takanori Matsuura, Mayumi Ehara, Tatsuya Sakane, Miki Kawano, Yuta Inoue, Shoji Tamura, Aya Horai, Yuuki Shiomi, Yoshihiko Yano, Yuzo Kodama

  AIMS: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; however, they are associated with ICI-induced liver injury (ICI-LI), which manifests as hepatocellular, mixed, or cholestatic patterns with variable treatment responses. This study aimed to develop and validate a predictive model to identify ICI-LI type using clinical data available at ICI initiation. METHODS: A retrospective analysis of 297 patients with ICI-LI was conducted. Baseline clinical data were analyzed using univariate and multivariate logistic regression to predict ICI-LI types in the training and validation cohorts. A predictive model was developed and validated using receiver operating characteristic (ROC) curve analysis. RESULTS: Multivariate analysis in the training cohort identified male sex (odds ratio [OR]: 3.33, 95% confidence interval [CI]: 1.57-7.06, p = 0.002), serum albumin levels (OR: 0.42, 95% CI: 0.19-0.91, p = 0.027), and serum alanine aminotransferase (ALT) levels (OR: 0.97, 95% CI: 0.94-0.99, p = 0.015) as significant predictors, along with ICI regimen types selected using the Akaike information criterion. The logistic regression model, expressed as p = 1/{1 + (-(5.02 + 1.20 × (sex [F:0, M:1])) - 0.87 × albumin [g/dL] - 0.03 × ALT [U/L] - 0.9 × (drug [non-anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) related regimen:0, anti-CTLA-4 related regimen:1]))}, achieved an area under the ROC (AUROC) of 0.73 (95% CI: 0.63-0.82) in the training cohort. At a cut-off of 0.86, the sensitivity was 60.3%, specificity 74.4%, positive predictive value 92.3%, and negative predictive value 26.9%. In the validation cohort, the AUROC was 0.752 (95% CI: 0.476-1.00). CONCLUSION: This predictive model demonstrates its utility in classifying ICI-LI types.

  Apr. 2025, JGH open : an open access journal of gastroenterology and hepatology, 9(4) (4), e70147, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Immunoscore Predicted by Dynamic Contrast-Enhanced Computed Tomography Can Be a Non-Invasive Biomarker for Immunotherapy Susceptibility of Hepatocellular Carcinoma.

  Eisuke Ueshima, Keitaro Sofue, Shohei Komatsu, Nobuaki Ishihara, Masato Komatsu, Akihiro Umeno, Kentaro Nishiuchi, Ryohei Kozuki, Takeru Yamaguchi, Takanori Matsuura, Toshifumi Tada, Takamichi Murakami

  Background/Objectives: Although immunotherapy is the primary treatment option for intermediate-stage hepatocellular carcinoma (HCC), its efficacy varies. This study aimed to identify non-invasive imaging biomarkers predictive of the immunoscore linked to dynamic contrast-enhanced computed tomography (CECT). Methods: We performed immunohistochemical staining with CD3+ and CD8+ antibodies and counted the positive cells in the invasive margin (IM) and central tumor (CT), converting them to an immunoscore of 0 to 4 points. We assessed the dynamic CECT findings obtained from 96 patients who underwent hepatectomy for HCC and evaluated the relationship between dynamic CECT findings and immunoscores. For validation, we assessed the treatment effects on 81 nodules using the Response Evaluation Criteria in Solid Tumors in another cohort of 41 patients who received combined immunotherapy with atezolizumab and bevacizumab (n = 27) and durvalumab and tremelizumab (n = 14). Results: HCCs with peritumoral enhancement in the arterial phase (p < 0.001) and rim APHE (p = 0.009) were associated with the immunoscore in univariate linear regression analysis and peritumoral enhancement in the arterial phase (p = 0.004) in multivariate linear regression analysis. The time to nodular progression in HCCs with peritumoral enhancement in the arterial phase was significantly longer than that in HCCs without this feature (p < 0.001). Conclusions: We identified HCCs with peritumoral enhancement in the arterial phase as a noninvasive imaging biomarker to predict immune-inflamed HCC with a high immunoscore tendency. These HCCs were most likely to respond to combined immunotherapy.

  Mar. 2025, Cancers, 17(6) (6), English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• The potential efficacy of atezolizumab plus bevacizumab treatment for hepatocellular carcinoma patients with macroscopic portal vein tumor thrombus.

  Shohei Komatsu, Yoshihiko Yano, Kazuki Terashima, Yoshimi Fujishima, Jun Ishida, Nobuaki Ishihara, Takanori Matsuura, Tomoaki Okimoto, Yuzo Kodama, Takumi Fukumoto

  PURPOSE: The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) in the first-order or main trunk/contralateral branches (Vp3/4) is poor. The present study aimed to clarify the real-world data of atezolizumab plus bevacizumab treatment (Ate/bev) for HCC patients with Vp3/4 PVTT. METHODS: The subjects of this study were 22 consecutive HCC patients with Vp3/4 PVTT, who were treated with Ate/bev. Survival rates and radiological responses were evaluated based on the modified albumin-bilirubin (mALBI) grade [mALBI 1 + 2a (1/2a) versus 2b + 3 (2b/3)] using the modified Response Evaluation Criteria in Solid Tumors. RESULTS: The median survival time of the 22 patients was 15.0 months, with 1- and 2-year survival rates of 62.7% and 49.3%, respectively. The objective response (OR) rates of patients with mALBI 1/2a and 2b/3 were 91.7% (11/12) and 10.0% (1/10), respectively, with a significant difference (p < 0.001). The 2-year survival rates of patients with mALBI 1/2a and 2b/3 were 78.6% and 20.0%, respectively, with a significant difference (p = 0.0041). CONCLUSION: Ate/bev was effective for treating HCC patients with Vp3/4 PVTT. OR rate and MST were favorable, particularly for patients with preserved liver function (mALBI 1/2a), suggesting its great potential for the treatment of HCC in patients with Vp3/4 PVTT.

  Feb. 2025, Surgery today, 55(7) (7), 900 - 908, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Higher Absolute Lymphocyte Counts and Lower Des-γ-Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Combination Therapy for Hepatocellular Carcinoma.

  Yuta Inoue, Yoshihiko Yano, Saeko Kushida, Seiya Hirohata, Seitetsu Yoon, Eiichiro Yasutomi, Hirotaka Hirano, Soo Ki Kim, Ryutaro Yoshida, Yoshihide Ueda, Kenji Momose, Hiroki Hayashi, Takuo Kado, Katsuhisa Nishi, Hidenori Tanaka, Tomomitsu Matono, Atsushi Yamamoto, Hiroshi Tei, Chiharu Nishioka, Yosuke Yagi, Shoji Tamura, Tatsuya Sakane, Mayumi Ehara, Miki Kawano, Jun Kitadai, Takanori Matsuura, Yuuki Shiomi, Shohei Komatsu, Takumi Fukumoto, Toshifumi Tada, Yuzo Kodama

  BACKGROUND AND AIMS: Tremelimumab plus durvalumab (Dur/Tre) combination therapy is now a first-line systemic therapy for advanced hepatocellular carcinoma (HCC). Because systemic therapy is not effective in some patients, it is clinically important to identify factors that could predict the response to treatment at an early stage. We investigated the factors associated with the response to Dur/Tre for advanced HCC in a clinical setting. METHODS: Seventy patients (median age 74 years; 61 men) who received Dur/Tre between March 2023 and September 2024 were analyzed. We examined the factors associated with the treatment response, including pretreatment factors and factors early in treatment. RESULTS: The median treatment duration was 77.5 (interquartile range [IQR] 28-187) days. The overall response and disease control rates were 25.8% and 58.1%, respectively. The median (IQR) progression-free survival (PFS) and overall survival (OS) were 82 (61-133) and 415 (337-NA) days, respectively. Multivariable analysis revealed that higher absolute lymphocyte count (ALC) and lower des-γ-carboxyprothrombin (DCP) levels were significantly associated with PFS. Receiver operating characteristic curve analysis showed that the cutoff value for ALC after 4 weeks of treatment in relation to clinical efficacy was 1125/mm3. A log-rank test using the Kaplan-Meier method showed that OS was significantly longer in patients with ALC above the cutoff and in patients whose DCP levels decreased after starting treatment. CONCLUSION: Higher ALC and lower DCP levels after treatment initiation were associated with the clinical efficacy of Dur/Tre for advanced HCC.

  Feb. 2025, JGH open : an open access journal of gastroenterology and hepatology, 9(2) (2), e70123, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.

  Nobuaki Ishihara, Shohei Komatsu, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Kentaro Tai, Keisuke Arai, Hiroaki Yanagimoto, Hirochika Toyama, Takanori Matsuura, Toshifumi Tada, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: Atezolizumab plus bevacizumab (AteBev) is widely used as a first-line treatment for advanced hepatocellular carcinoma (HCC). However, evidence regarding the optimal drug sequence following AteBev treatment is limited. This study aimed to compare the treatment outcomes between tyrosine kinase inhibitors (TKIs) and durvalumab plus tremelimumab (DurTre) following AteBev treatment. PATIENTS AND METHODS: Overall, 134 consecutive patients who received AteBev for advanced HCC were enrolled in this study. Treatment outcomes were retrospectively compared between TKIs (AteBev→TKI group) and DurTre (AteBev→DurTre group). RESULTS: The AteBev→TKI and Ate→DurTre groups included 46 and 7 patients, respectively. The AteBev→TKI group had significantly longer median progression-free survival after second-line treatment (3.6 vs. 0.94 months, p<0.001). The disease control rate was significantly higher in the AteBev→TKI group (p=0.020). The serum alpha-fetoprotein levels significantly decreased at one month in the AteBev→TKI group (0.909 vs. 1.435, p=0.035), whereas the albumin-bilirubin score significantly decreased at one month in the AteBev→TKI group (0.875 vs. 0.952, p=0.017). Each group reported no new unmanageable adverse events. CONCLUSION: TKIs may be a more optimal drug sequence than DurTre after AteBev treatment from an oncological perspective. TKIs following AteBev treatment require careful monitoring for deteriorating liver function.

  International Institute of Anticancer Research, Jan. 2025, Anticancer research, 45(1) (1), 251 - 260, English, International magazine

  Scientific journal


• 当院におけるデュルバルマブ・トレメリムマブ療法の初期使用成績

  井上 裕太, 矢野 嘉彦, 江原 真由実, 坂根 達哉, 田村 証司, 河野 未樹, 北代 隼, 山本 淳史, 蓬莱 亞矢, 松浦 敬憲, 塩見 優紀, 小松 昇平, 多田 俊史, 福本 巧, 児玉 裕三

  (一社)日本肝臓学会, Oct. 2024, 肝臓, 65(Suppl.3) (Suppl.3), A861 - A861, Japanese


• 食道静脈瘤に対するRed Dichromatic Imagingを用いた治療戦略

  山本 淳史, 松浦 敬憲, 田村 証司, 河野 未樹, 井上 裕太, 北代 隼, 吉田 竜太郎, 塩見 優紀, 矢野 嘉彦, 上田 佳秀, 児玉 裕三

  (一社)日本肝臓学会, Sep. 2024, 肝臓, 65(Suppl.2) (Suppl.2), A679 - A679, Japanese


• Diagnostic guide for immune checkpoint inhibitor-induced liver injury.

  Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru, Kazumichi Abe, Masanori Abe, Takanori Matsuura, Masataka Yokode, Masahiro Shiokawa, Yuzo Kodama, Mina Komuta, Kenichi Harada, Atsushi Tanaka

  With the widespread use of immune checkpoint inhibitors (ICIs), liver injury (ICI-induced liver injury) as an immune-related adverse event has become a major concern in clinical practice. Because severe cases of liver injury require administration of corticosteroids, a comprehensive evaluation is crucial, including clinical course, blood and imaging tests, and if necessary, pathological examination through liver biopsy. As with liver injury induced by other drugs, classification of injury type by R-value is useful in deciding treatment strategies for ICI-induced liver injury. Histologically, the most representative feature is an acute hepatitis-like hepatocellular injury, characterized by diffuse lobular inflammation accompanied by CD8-positive T lymphocytes. Another condition that can cause liver injury during ICI treatment is cholangitis accompanied by non-obstructive bile duct dilatation and bile duct wall thickening. Many cases of ICI-induced cholangitis are classified as non-hepatocellular injury type, and they have been reported to respond poorly to corticosteroids. It is essential that gastroenterologists/hepatologists and doctors in various departments work in cooperation to develop a system that achieves early diagnosis and appropriate treatment of ICI-induced liver injury.

  Aug. 2024, Hepatology research : the official journal of the Japan Society of Hepatology, 54(8) (8), 719 - 726, English, International magazine

  Scientific journal


• Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy.

  Miki Kawano, Yoshihiko Yano, Atsushi Yamamoto, Eiichiro Yasutomi, Yuta Inoue, Jun Kitadai, Ryutaro Yoshida, Takanori Matsuura, Yuuki Shiomi, Yoshihide Ueda, Yuzo Kodama

  Immune checkpoint inhibitor (ICI)-induced liver injury (LI) is a common adverse event, but the clinical characteristics based on the classification of hepatocellular injury and cholestatic types are not fully evaluated. This study aims to analyze risk factors and histological findings in relation to the classification of ICI-induced LI. In total, 254 ICI-induced LI patients among 1086 treated with ICIs between September 2014 and March 2022 were classified according to the diagnostic criteria for drug-induced LI (DILI), and their risk factors and outcomes were evaluated. Kaplan-Meier analyses showed that overall survival in patients with hepatocellular-injury-type LI was significantly longer than others (p < 0.05). Regarding pre-treatment factors, the lymphocyte count was significantly higher in patients with ICI-induced LI, especially in hepatocellular-injury-type LI. Gamma glutamyl transferase (γGTP) and alkaline phosphatase (ALP) were also significantly lower in patients with ICI-induced LI (p < 0.05). Multivariate analyses revealed that malignant melanoma, high lymphocyte count, and low ALP levels were extracted as factors contributing to hepatocellular-injury-type LI. The histological findings among 37 patients diagnosed as ICI-induced LI via liver biopsy also revealed that the spotty/focal necrosis was significantly frequent in hepatocellular-injury-type LI, whereas ductular reactions were frequently observed in cholestatic-type LI. It is suggested that the histological inflammation pattern in patients with LI is closely correlated with the type of DILI.

  Apr. 2024, Diagnostics (Basel, Switzerland), 14(8) (8), English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• ICI使用中肝障害における肝生検の意義

  矢野 嘉彦, 山本 淳史, 河野 未樹, 吉田 竜太郎, 井上 裕太, 北代 隼, 蓬莱 亞矢, 松浦 敬憲, 上田 佳秀, 児玉 裕三

  (一社)日本肝臓学会, Apr. 2024, 肝臓, 65(Suppl.1) (Suppl.1), A356 - A356, Japanese


• Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen.

  Yoshihiko Yano, Itsuko Sato, Takamitsu Imanishi, Ryutaro Yoshida, Takanori Matsuura, Yoshihide Ueda, Yuzo Kodama

  Currently, hepatitis B virus (HBV) core antibody (anti-HBc antibody) and HBV core-related antigen (HBcrAg) are widely used as serum markers for diagnosis based on the HBV core region. This review focused on anti-HBc antibodies and HBcrAg and aimed to summarize the clinical significance of currently used assay systems and the issues involved. While anti-HBc is very significant for clinical diagnosis, the clinical significance of quantitative assay of anti-HBc antibody has been reevaluated with improvements in diagnostic performance, including its association with clinical stage and prediction of carcinogenesis and reactivation. In addition, concerning the new HBcrAg, a high-sensitivity assay method has recently been established, and its diagnostic significance, including the prediction of reactivation, is being reevaluated. On the other hand, the quantitative level of anti-HBc antibody expressed in different units among assay systems complicates the interpretation of the results. However, it is difficult to standardize assay systems as they vary in advantages, and caution is needed in interpreting the assay results. In conclusion, with the development of highly sensitive HBcrAg and anti-HBc antibody, a rapid and sensitive detection assay system has been developed and used in clinical practice. In the future, it is hoped that a global standard will be created based on the many clinical findings.

  Mar. 2024, Diagnostics (Basel, Switzerland), 14(7) (7), English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Histological diagnosis of polyploidy discriminates an aggressive subset of hepatocellular carcinomas with poor prognosis.

  Takanori Matsuura, Yoshihide Ueda, Yoshiyuki Harada, Kazuki Hayashi, Kisara Horisaka, Yoshihiko Yano, Shinichi So, Masahiro Kido, Takumi Fukumoto, Yuzo Kodama, Eiji Hara, Tomonori Matsumoto

  BACKGROUND: Although genome duplication, or polyploidization, is believed to drive cancer evolution and affect tumor features, its significance in hepatocellular carcinoma (HCC) is unclear. We aimed to determine the characteristics of polyploid HCCs by evaluating chromosome duplication and to discover surrogate markers to discriminate polyploid HCCs. METHODS: The ploidy in human HCC was assessed by fluorescence in situ hybridization for multiple chromosomes. Clinicopathological and expression features were compared between polyploid and near-diploid HCCs. Markers indicating polyploid HCC were explored by transcriptome analysis of cultured HCC cells. RESULTS: Polyploidy was detected in 36% (20/56) of HCCs and discriminated an aggressive subset of HCC that typically showed high serum alpha-fetoprotein, poor differentiation, and poor prognosis compared to near-diploid HCCs. Molecular subtyping revealed that polyploid HCCs highly expressed alpha-fetoprotein but did not necessarily show progenitor features. Histological examination revealed abundant polyploid giant cancer cells (PGCCs) with a distinct appearance and frequent macrotrabecular-massive architecture in polyploid HCCs. Notably, the abundance of PGCCs and overexpression of ubiquitin-conjugating enzymes 2C indicated polyploidy in HCC and efficiently predicted poor prognosis in combination. CONCLUSIONS: Histological diagnosis of polyploidy using surrogate markers discriminates an aggressive subset of HCC, apart from known HCC subgroups, and predict poor prognosis in HCC.

  Oct. 2023, British journal of cancer, 129(8) (8), 1251 - 1260, English, International magazine

  Scientific journal


• ヒト肝細胞癌病理組織における多倍体化評価法の確立と臨床病理学的特徴の検討

  松浦 敬憲, 上田 佳秀, 河野 未樹, 井上 裕太, 北代 隼, 朝治 直紀, 山本 淳史, 吉田 竜太郎, 南 晶洋, 塩見 優紀, 矢野 嘉彦, 木戸 正浩, 福本 巧, 児玉 裕三, 松本 知訓

  (一社)日本肝臓学会, Sep. 2023, 肝臓, 64(Suppl.2) (Suppl.2), A625 - A625, Japanese


• 不均一性を有するヒト膵臓癌関連線維芽細胞の臨床経過による動態(Dynamics of heterogenous cancer-associated fibroblasts in human pancreatic cancers in the clinical course)

  原田 宜幸, 松本 知訓, 林 計企, 松浦 敬憲, 増田 充弘, 児玉 裕三, 原 英二

  (一社)日本癌学会, Sep. 2023, 日本癌学会総会記事, 82回, 1997 - 1997, English


• A Case of Duodenal Edema-related Undiagnosed Hereditary Angioedema.

  Fumiaki Kawara, Takanori Matsuura, Kodai Yamanaka, Chiharu Nishioka

  Aug. 2023, Internal medicine (Tokyo, Japan), 62(15) (15), 2285 - 2286, English, Domestic magazine

  Scientific journal


• Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma.

  Yoshihiko Yano, Atsushi Yamamoto, Takuya Mimura, Saeko Kushida, Seiya Hirohata, Seitetsu Yoon, Hirotaka Hirano, Soo Ki Kim, Yuri Hatazawa, Kenji Momose, Hiroki Hayashi, Takuo Kado, Katsuhisa Nishi, Hidenori Tanaka, Takanori Matsuura, Ryutaro Yoshida, Naoki Asaji, Eiichiro Yasutomi, Yuuki Shiomi, Akihiro Minami, Shohei Komatsu, Takumi Fukumoto, Yoshihide Ueda, Yuzo Kodama

  BACKGROUND AND AIM: The purpose of this study was to analyze factors associated with the overall survival (OS) of atezolizumab/bevacizumab combination therapy for advanced hepatocellular carcinoma (aHCC). We also assessed the OS of patients with ineffective therapy and those who discontinued treatment owing to adverse events (AEs). METHODS: This retrospective multicenter study involved 139 patients with aHCC who received atezolizumab/bevacizumab combination therapy between November 2020 and September 2022. RESULTS: The median duration of treatment was 136.5 days, and the median observation period was 316 days. The overall response rate was 40%, and the disease control rate was 78% according to mRECIST criteria. Grade ≥2 AEs occurred in 63 patients (43%) and led to treatment discontinuation in 16 patients. Multivariate analysis revealed that treatment response and occurrence of grade ≥2 AEs after therapy, as well as low level of albumin-bilirubin (ALBI) grade and low level of des-gamma carboxy prothrombin (DCP) before therapy, were extracted as factors that contributed to OS. Log-rank tests with the Kaplan-Meier method showed significant differences in OS among these factors. The OS of patients who discontinued owing to AEs was significantly shorter than that of other patients. CONCLUSION: Not only factors before therapy but also treatment response and the appearance of AEs are involved in OS for atezolizumab/bevacizumab combination therapy. Although the development of AEs also contributed to OS, appropriate management of AEs is important to avoid discontinuing treatment with this combination.

  Jul. 2023, JGH open : an open access journal of gastroenterology and hepatology, 7(7) (7), 476 - 481, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Endoscopic closure of cecal fistula using purse-string suture after plombage with polyglycolic acid sheets and fibrin glue.

  Fumiaki Kawara, Akihiro Minami, Kazuya Hara, Kodai Yamanaka, Takanori Matsuura, Mitsuko Mimura, Chiharu Nishioka

  Nov. 2022, Endoscopy, 54(11) (11), E662-E663, English, International magazine

  Scientific journal


• 急速な転帰を辿った胆嚢未分化癌の1例

  井上 裕太, 安冨 栄一郎, 矢野 嘉彦, 河野 未樹, 北代 隼, 朝治 直紀, 吉田 竜太郎, 山本 淳史, 松浦 敬憲, 南 晶洋, 塩見 優紀, 上田 佳秀, 児玉 裕三

  (一社)日本肝臓学会, Oct. 2022, 肝臓, 63(Suppl.3) (Suppl.3), A808 - A808, Japanese


• Significance of post-progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma.

  Yoshihiko Yano, Atsushi Yamamoto, Akihiro Minami, Kenji Momose, Takuya Mimura, Soo Ki Kim, Hiroki Hayashi, Takuo Kado, Hirotaka Hirano, Seiya Hirohata, Seitetsu Yoon, Katsuhisa Nishi, Hiroshi Tei, Hidenori Tanaka, Sachiko Oouchi, Takanori Matsuura, Eiichiro Yasutomi, Yuri Hatazawa, Yuuki Shiomi, Yoshihide Ueda, Yuzo Kodama

  BACKGROUND AND AIM: Molecular-targeted therapies such as sorafenib and lenvatinib have long been used as first-line treatment for advanced hepatocellular carcinoma (aHCC). However, adverse events or limited therapeutic effects may necessitate the change to another therapeutic option, known as post-progression therapy. To investigate the significance of post-progression therapy, we analyzed the outcomes of aHCC patients following first-line molecular-targeted therapy in a real-world study. METHODS: This retrospective, multicenter study involved patients with aHCC who received sorafenib or lenvatinib as first-line therapy between January 2011 and September 2021. RESULTS: In total, 513 patients were analyzed: 309 treated with sorafenib and 204 with lenvatinib. The overall response and disease control rates were 15 and 50%, respectively, in the sorafenib group and 30 and 75%, respectively, in the lenvatinib group (P < 0.001). Kaplan-Meier analysis revealed no significant differences in progression-free survival and overall survival (OS) between the two treatments. Multivariate analysis revealed that fibrosis-4 index, disease control rate, post-progression therapy, and use of an immune checkpoint inhibitor (ICI) were significantly associated with OS. OS was significantly longer in patients who received post-progression therapy than in those who did not (log-rank P < 0.001). Most patients who received an ICI as post-progression therapy had previously received lenvatinib. Among lenvatinib-treated patients, OS was significantly longer in patients who received an ICI than in patients received another or no post-progression therapy (P = 0.004). CONCLUSION: The introduction of newer drugs for post-progression therapy is expected to prolong survival. ICI-based regimens appear to be effective after lenvatinib.

  Jun. 2022, JGH open : an open access journal of gastroenterology and hepatology, 6(6) (6), 427 - 433, English, International magazine

  Scientific journal


• 肝細胞癌に対するがん免疫療法に伴う消化器系出血の検討

  北代 隼, 山本 淳史, 矢野 嘉彦, 小松 昇平, 朝治 直紀, 吉田 竜太郎, 安冨 栄一郎, 松浦 敬憲, 畑澤 友里, 塩見 優紀, 上田 佳秀, 福本 巧, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Dec. 2021, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 107回, 125 - 125, Japanese

• 高齢者におけるSTRIDEレジメンの有効性と安全性

  多田 俊史, 熊田 卓, 平岡 淳, 谷 丈二, 厚川 正則, 高口 浩一, 糸林 詠, 辻 邦彦, 石川 達, 玉井 秀幸, 豊田 秀徳, 畑中 健, 柿崎 暁, 能祖 一裕, 松浦 敬憲, 小松 昇平, 黒田 英克, 海堀 昌樹, 日浅 陽一, 工藤 正俊

  (株)アークメディア, May 2026, 肝胆膵, 92(5) (5), 634 - 636, Japanese


• 肝細胞癌腫瘍学的切除可能性分類に基づいた肝切除および薬物療法治療成績の検証

  小松 昇平, 多田 俊史, 上嶋 英介, 松浦 敬憲, 祖父江 慶太郎, 木戸 正浩, 福島 健司, 浦出 剛史, 吉田 俊彦, 荒井 啓輔, 南野 佳英, 柳本 泰明, 児玉 裕三, 村上 卓道, 福本 巧

  (株)アークメディア, Jan. 2026, 肝胆膵, 92(1) (1), 112 - 114, Japanese


• 消化器癌におけるConversion Surgeryの課題と展望 切除不能進行肝細胞癌に対するアテゾリズマブ・ベバシズマブ併用療法後コンバージョン治療の意義

  福島 健司, 小松 昇平, 松浦 敬憲, 木戸 正浩, 浦出 剛史, 南野 佳英, 浅利 貞毅, 柳本 泰明, 多田 俊史, 福本 巧

  日本消化器病学会-近畿支部, Jan. 2026, 日本消化器病学会近畿支部例会プログラム・抄録集, 124回, 63 - 63, Japanese


• アバコパンによる薬物性肝障害を発症した2例

  藤本 涼, 北代 隼, 江原 真由実, 坂根 達哉, 新丸 尚輝, 河野 未樹, 井上 裕太, 松浦 敬憲, 南 晶洋, 塩見 優紀, 多田 俊史, 児玉 裕三

  日本消化器病学会-近畿支部, Jan. 2026, 日本消化器病学会近畿支部例会プログラム・抄録集, 124回, 104 - 104, Japanese


• The impact of polyploidy on the pathogenesis of human intrahepatic cholangiocarcinoma

  Kenji Nagata, Takanori Matsuura, Taku Kitano, Kazuki Hayashi, Miki Kawano, Yuzo Kodama, Eiji Hara, Tomonori Matsumoto

  Jan. 2026, CANCER SCIENCE, 117, 881 - 881, English

  Summary international conference


• 当院におけるICU管理後の肝移植の治療成績

  荒井 啓輔, 小松 昇平, 福島 健司, 滝本 大輔, 木戸 正浩, 浦出 剛史, 宗 慎一, 吉田 俊彦, 田井 謙太郎, 井口 浩輔, 南野 佳英, 柳本 泰明, 松浦 敬憲, 福本 巧

  (一社)日本移植学会, Oct. 2025, 移植, 60, 342 - 342, Japanese


• 免疫チェックポイント阻害薬による肝障害の診断・治療指針 2025

  伊藤 隆徳, 竹内 康人, 水野 和幸, 今井 径卓, 吉丸 洋子, 阿部 和道, 阿部 雅則, 松浦 敬憲, 横出 正隆, 塩川 雅広, 小笠原 定久, 児玉 裕三, 小無田 美菜, 原田 憲一, 坂本 直哉, 田中 篤, 日本肝臓学会企画広報委員会薬物性肝障害ワーキンググループ

  (一社)日本肝臓学会, Sep. 2025, 肝臓, 66(9) (9), 375 - 387, Japanese


• 肝細胞癌に対する治療戦略 切除不能肝細胞癌に対するDurvalumab/Tremelimumab併用療法の治療成績

  中田 有哉, 山本 淳史, 的野 智光, 櫛田 早絵子, 百瀬 健次, 平野 仁崇, 八木 洋輔, 上田 佳秀, 松浦 敬憲, 多田 俊史

  日本消化器病学会-近畿支部, Sep. 2025, 日本消化器病学会近畿支部例会プログラム・抄録集, 123回, 54 - 54, Japanese


• 肝細胞癌に対する治療戦略 mALF scoreはデュルバルマブ/トレメリムマブが投与された肝細胞癌に対する予後予測マーカーである

  北代 隼, 多田 俊史, 松浦 敬憲, 新丸 尚輝, 坂根 達哉, 江原 真由実, 河野 未樹, 井上 裕太, 小松 昇平, 児玉 裕三

  日本消化器病学会-近畿支部, Sep. 2025, 日本消化器病学会近畿支部例会プログラム・抄録集, 123回, 54 - 54, Japanese


• 肝細胞癌に対する治療戦略 アテゾリズマブ・ベバシズマブ併用療法後コンバージョン治療の検討

  佐野 隼大, 小松 昇平, 多田 俊史, 上嶋 英介, 松浦 敬憲, 祖父江 慶太郎, 福島 健司, 木戸 正浩, 児玉 裕三, 福本 巧

  日本消化器病学会-近畿支部, Sep. 2025, 日本消化器病学会近畿支部例会プログラム・抄録集, 123回, 55 - 55, Japanese


• 肝細胞癌に対する全身薬物療法中に低血糖による意識障害をきたした一例

  山上 拓真, 角谷 環子, 東 裕介, 菅原 一馬, 西川 浩介, 中辻 政志, 阿部 晶平, 木下 雅登, 山中 広大, 松浦 敬憲, 西岡 千晴, 矢野 嘉彦

  日本消化器病学会-近畿支部, Sep. 2025, 日本消化器病学会近畿支部例会プログラム・抄録集, 123回, 101 - 101, Japanese


• アテゾリズマブ/ベバシズマブ併用療法例におけるCRP-albumin比の予後予測における有用性

  松浦 敬憲, 多田 俊史, 小松 昇平, 西村 貴士, 福本 巧, 児玉 裕三

  (一社)日本肝臓学会, Sep. 2025, 肝臓, 66(Suppl.2) (Suppl.2), A636 - A636, Japanese


• アテゾリズマブ/ベバシズマブ併用療法が投与されたChild-Pugh分類B症例の検討

  江原 真由実, 多田 俊史, 松浦 敬憲, 小松 昇平, 福本 巧, 西村 貴士, 児玉 裕三

  (一社)日本肝臓学会, Sep. 2025, 肝臓, 66(Suppl.2) (Suppl.2), A638 - A638, Japanese


• 肝内胆管癌における多倍体癌の特徴に関する探求(The impact of polyploidy on the pathogenesis of human intrahepatic cholangiocarcinoma)

  長田 健司, 松浦 敬憲, 北野 拓, 林 計企, 河野 未樹, 児玉 裕三, 原 英二, 松本 知訓

  (一社)日本癌学会, Sep. 2025, 日本癌学会総会記事, 84回, 881 - 881, English


• 認知機能の精査で,非硬変肝に生じた多発微小肝内門脈肝静脈短絡症による肝性脳症の診断に至った一例

  江原 真由実, 多田 俊史, 坂根 達哉, 井上 裕太, 河野 未樹, 田村 証司, 北代 隼, 蓬莱 亞矢, 塩見 優紀, 松浦 敬憲, 矢野 嘉彦, 児玉 裕三

  (一社)日本肝臓学会, Jun. 2025, 肝臓, 66(6) (6), 241 - 248, Japanese


• アテゾリズマブ・ベバシズマブ併用療法後の局所治療 導入のタイミング,モダリティー,その後の薬物療法の継続の是非に関する検討

  石原 伸朗, 小松 昇平, 矢野 嘉彦, 寺嶋 千貴, 藤島 佳未, 石田 淳, 木戸 正浩, 権 英寿, 福島 健司, 浦出 剛史, 吉田 俊彦, 田井 謙太郎, 荒井 啓輔, 柳本 泰明, 外山 博近, 松浦 敬憲, 多田 俊史, 徳丸 直郎, 沖本 智昭, 福本 巧

  (一社)日本外科学会, Apr. 2025, 日本外科学会定期学術集会抄録集, 125回, SF - 4, Japanese


• 当科における腫瘍学的切除可能性分類定義に基づいた肝切除・薬物療法成績の検討

  田井 謙太郎, 小松 昇平, 矢野 嘉彦, 木戸 正浩, 権 英寿, 福島 健司, 浦出 剛, 宗 慎一, 吉田 俊彦, 荒井 啓輔, 秋田 真之, 水本 拓也, 石田 潤, 南野 佳英, 津川 大介, 浅利 貞毅, 柳本 泰明, 外山 博近, 松浦 敬憲, 福本 巧

  (一社)日本外科学会, Apr. 2025, 日本外科学会定期学術集会抄録集, 125回, PS - 7, Japanese


• 薬物性肝障害の現状と展望 ICIによる肝障害パターンの予測因子の検討

  北代 隼, 多田 俊史, 松浦 敬憲

  (一社)日本肝臓学会, Apr. 2025, 肝臓, 66(Suppl.1) (Suppl.1), A144 - A144, Japanese


• アテゾリズマブ・ベバシズマブ併用療法後の根治を企図した粒子線治療の短期成績

  石原 伸朗, 小松 昇平, 寺嶋 千貴, 多田 俊史, 矢野 嘉彦, 松浦 敬憲, 大森 將貴, 木戸 正浩, 権 英寿, 福島 健司, 浦出 剛史, 吉田 俊彦, 田井 謙太郎, 荒井 啓輔, 水本 拓也, 南野 佳英, 徳丸 直郎, 沖本 智昭, 児玉 裕三, 福本 巧

  (一社)日本肝臓学会, Apr. 2025, 肝臓, 66(Suppl.1) (Suppl.1), A376 - A376, Japanese


• リンパ球・単球比はデュルバルマブ/トレメリムマブが投与された肝細胞癌に対する予後予測バイオマーカーである

  坂根 達哉, 井上 裕太, 松浦 敬憲, 多田 俊史, 矢野 嘉彦, 櫛田 早絵子, 鄭 浩柄, 平野 仁崇, 西岡 千晴, 八木 洋輔, 児玉 裕三

  (一社)日本肝臓学会, Apr. 2025, 肝臓, 66(Suppl.1) (Suppl.1), A385 - A385, Japanese


• 治療開始後早期のリンパ球数高値とPIVKA-IIの低下は,肝細胞癌に対するDT療法の臨床的有効性と関連がある

  井上 裕太, 矢野 嘉彦, 坂根 達哉, 江原 真由実, 田村 証司, 河野 未樹, 北代 隼, 蓬莱 亞矢, 松浦 敬憲, 塩見 優紀, 多田 俊史, 小松 昇平, 鄭 浩柄, 百瀬 健次, 櫛田 早絵子, 児玉 裕三

  (一社)日本肝臓学会, Apr. 2025, 肝臓, 66(Suppl.1) (Suppl.1), A394 - A394, Japanese


• アテゾリズマブ・ベバシズマブ併用療法後のチロシンキナーゼ阻害薬とデュルバルマブ・トレメリムマブ併用療法の治療成績に関する比較検討

  田井 謙太郎, 小松 昇平, 石原 伸朗, 矢野 嘉彦, 木戸 正浩, 権 英寿, 福島 健司, 浦出 剛史, 吉田 俊彦, 荒井 啓輔, 水本 拓也, 南野 佳英, 津川 大介, 浅利 貞毅, 松浦 敬憲, 多田 俊史, 福本 巧

  (一社)日本肝臓学会, Apr. 2025, 肝臓, 66(Suppl.1) (Suppl.1), A395 - A395, Japanese


• AI診断モデルを活用した,多倍体肝細胞癌に対する免疫チェックポイント阻害薬の有効性の検討

  松浦 敬憲, 多田 俊史, 矢野 嘉彦, 児玉 裕三, 上田 佳秀, 松本 知訓

  (一社)日本肝臓学会, Apr. 2025, 肝臓, 66(Suppl.1) (Suppl.1), A426 - A426, Japanese


• 切除不能肝細胞癌に対するアテゾリズマブ・ベバシズマブ併用療法リチャレンジの治療成績

  濱中 統親, 小松 昇平, 多田 俊史, 石原 伸朗, 大森 將貴, 木戸 正浩, 権 英寿, 福島 健司, 浦出 剛史, 吉田 俊彦, 田井 謙太郎, 荒井 啓輔, 水本 拓也, 南野 佳英, 津川 大介, 浅利 貞毅, 松浦 敬憲, 矢野 嘉彦, 児玉 裕三, 福本 巧

  (一社)日本肝臓学会, Apr. 2025, 肝臓, 66(Suppl.1) (Suppl.1), A456 - A456, Japanese


• 進行肝細胞癌薬物療法における転移部位別奏効率の検討

  大森 將貴, 小松 昇平, 多田 俊史, 石原 伸朗, 木戸 正浩, 権 英寿, 福島 健司, 浦出 剛史, 吉田 俊彦, 田井 謙太郎, 荒井 啓輔, 水本 拓也, 南野 佳英, 津川 大介, 松浦 敬憲, 矢野 嘉彦, 児玉 裕三, 福本 巧

  (一社)日本肝臓学会, Apr. 2025, 肝臓, 66(Suppl.1) (Suppl.1), A467 - A467, Japanese


• 【肝・胆・膵がんの薬物療法のupdate】肝細胞がん 切除不能肝細胞がんに対する全身薬物療法の新展開

  多田 俊史, 平岡 淳, 畑中 健, 豊田 秀徳, 坂根 達哉, 江原 真由美, 河野 未樹, 井上 裕太, 北代 隼, 田村 証司, 蓬莱 亜矢, 松浦 敬憲, 塩見 優紀, 矢野 嘉彦, 児玉 裕三, 熊田 卓

  (有)科学評論社, Mar. 2025, 腫瘍内科, 35(3) (3), 240 - 247, Japanese


• 新時代を迎えた肝細胞癌治療と将来展望 進行肝細胞癌に対するアテゾリズマブ・ベバシズマブ併用療法によるdrug freeを目指した治療戦略

  大森 將貴, 小松 昇平, 石原 伸朗, 矢野 嘉彦, 寺嶋 千貴, 藤島 佳未, 石田 淳, 松浦 敬憲, 多田 俊史, 福本 巧

  日本消化器病学会-近畿支部, Feb. 2025, 日本消化器病学会近畿支部例会プログラム・抄録集, 122回, 52 - 52, Japanese


• 自己免疫性肝胆膵疾患に関する最新の話題 ICIによる肝障害パターンの予測因子の検討

  江原 真由実, 多田 俊史, 坂根 達哉, 田村 証司, 河野 未樹, 北代 隼, 塩見 優紀, 松浦 敬憲, 矢野 嘉彦, 児玉 裕三

  日本消化器病学会-近畿支部, Feb. 2025, 日本消化器病学会近畿支部例会プログラム・抄録集, 122回, 65 - 65, Japanese


• サイトメガロウイルス(CMV)感染を契機に門脈血栓症を発症した一例

  中川 篤志, 田中 秀憲, 山本 淳史, 松浦 敬憲, 矢野 嘉彦, 児玉 祐三

  日本消化器病学会-近畿支部, Feb. 2025, 日本消化器病学会近畿支部例会プログラム・抄録集, 122回, 90 - 90, Japanese


• 認知機能低下の精査で,非硬変肝に生じた多発肝内PVシャントによる肝性脳症の診断に至った一例

  吉田 美央, 江原 真由実, 松浦 敬憲, 多田 俊史, 坂根 達哉, 田村 証司, 河野 未樹, 塩見 優紀, 矢野 嘉彦, 児玉 裕三, 田中 秀憲

  日本消化器病学会-近畿支部, Feb. 2025, 日本消化器病学会近畿支部例会プログラム・抄録集, 122回, 91 - 91, Japanese


• Oncology emergency～あなたはどう対処していますか～ 進行肝細胞癌に対するatezolizumab+bevacizumab併用療法の合併症に関する検討

  石原 伸朗, 小松 昇平, 矢野 嘉彦, 木戸 正浩, 柳本 泰明, 外山 博近, 松浦 敬憲, 多田 俊史, 福本 巧

  (一社)日本腹部救急医学会, Feb. 2025, 日本腹部救急医学会雑誌, 45(2) (2), 223 - 223, Japanese


• Identification of senescence-like subtypes in pancreatic cancer-associated fibroblasts

  Yoshiyuki Harada, Tomonori Matsumoto, Takanori Matsuura, Atsuhiro Masuda, Yuzo Kodama, Eiji Hara

  Jan. 2025, CANCER SCIENCE, 116, 1019 - 1019, English

  Summary international conference


• 閉塞性黄疸で発見された肺低分化型扁平上皮癌十二指腸転移の1例

  原 和也, 河原 史明, 坂根 達哉, 田中 彩香, 賀来 英俊, 山中 広大, 松浦 敬憲, 高橋 卓也, 西岡 千晴

  (一社)日本消化器内視鏡学会, Dec. 2024, Gastroenterological Endoscopy, 66(12) (12), 2655 - 2661, Japanese


• 進行肝細胞癌に対する薬物療法を中心とした集学的治療

  石原 伸朗, 小松 昇平, 矢野 嘉彦, 寺島 千貴, 藤島 佳未, 石田 淳, 木戸 正浩, 権 英寿, 福島 健司, 浦出 剛史, 吉田 俊彦, 荒井 啓輔, 柳本 泰明, 外山 博近, 徳丸 直郎, 沖本 智昭, 松浦 敬憲, 上田 佳秀, 福本 巧

  (一社)日本消化器外科学会, Nov. 2024, 日本消化器外科学会雑誌, 57(Suppl.2) (Suppl.2), 338 - 338, Japanese


• 薬物性肝障害のマネジメント 免疫チェックポイント阻害薬による肝障害の障害型を予測する因子の検討

  松浦 敬憲, 多田 俊史, 児玉 裕三

  (一社)日本肝臓学会, Oct. 2024, 肝臓, 65(Suppl.3) (Suppl.3), A801 - A801, Japanese


• Budd-Chiari症候群を呈した肝類上皮血管内皮腫の1例

  坂根 達哉, 三井 綾佳, 江原 真由実, 田村 証司, 山本 淳史, 松浦 敬憲, 矢野 嘉彦, 児玉 裕三

  日本消化器病学会-近畿支部, Sep. 2024, 日本消化器病学会近畿支部例会プログラム・抄録集, 121回, 113 - 113, Japanese


• 前立腺癌に対するホルモン療法中にHBV再活性化を認めた1例

  田村 証司, 矢野 嘉彦, 三井 綾佳, 江原 真由実, 坂根 達哉, 山本 淳史, 松浦 敬憲, 児玉 裕三

  日本消化器病学会-近畿支部, Sep. 2024, 日本消化器病学会近畿支部例会プログラム・抄録集, 121回, 114 - 114, Japanese


• ACLF、High MELDなど重症症例に対する肝移植の適応限界 当院におけるhigh MELD score肝不全に対する肝移植の治療成績

  荒井 啓輔, 小松 昇平, 福島 健司, 志村 雄飛, 滝本 大輔, 木戸 正浩, 権 英寿, 浦出 剛史, 吉田 俊彦, 柳本 泰明, 外山 博近, 松浦 敬憲, 矢野 嘉彦, 上田 佳秀, 福本 巧

  (一社)日本移植学会, Sep. 2024, 移植, 59(総会臨時) (総会臨時), 198 - 198, Japanese


• 肝移植後MASLD発症を予測する因子に関する観察研究

  志村 雄飛, 小松 昇平, 荒井 啓輔, 木戸 正浩, 権 英寿, 福島 健司, 浦出 剛史, 吉田 俊彦, 柳本 泰明, 外山 博近, 松浦 敬憲, 矢野 嘉彦, 上田 佳秀, 福本 巧

  (一社)日本移植学会, Sep. 2024, 移植, 59(総会臨時) (総会臨時), 338 - 338, Japanese


• 膵癌関連線維芽細胞における、細胞老化様サブタイプの同定(Identification of senescence-like subtypes in pancreatic cancer-associated fibroblasts)

  原田 宜幸, 松本 知訓, 松浦 敬憲, 増田 充弘, 児玉 裕三, 原 英二, 松本 知訓

  (一社)日本癌学会, Sep. 2024, 日本癌学会総会記事, 83回, P - 2294, English


• 有症状にて治療介入をされたPoPH例の肝関連因子の検討

  田村 証司, 松浦 敬憲, 矢野 嘉彦, 山本 淳史, 吉田 竜太郎, 塩見 優紀, 上田 佳秀, 児玉 裕三

  (一社)日本肝臓学会, Sep. 2024, 肝臓, 65(Suppl.2) (Suppl.2), A682 - A682, Japanese


• 免疫チェックポイント阻害剤使用中の肝細胞障害型の免疫関連肝障害は,治療前のリンパ球数が高く,予後延長効果に関連する

  河野 未樹, 矢野 嘉彦, 田村 証司, 井上 裕太, 北代 隼, 山本 淳史, 吉田 竜太郎, 松浦 敬憲, 蓬莱 亞矢, 塩見 優紀, 上田 佳秀, 児玉 裕三

  (一社)日本肝臓学会, Apr. 2024, 肝臓, 65(Suppl.1) (Suppl.1), A356 - A356, Japanese


• AIを用いた消化器疾患の診断・治療への応用 AIを用いた肝細胞癌多倍体化診断モデルの作成とTCGA大規模データを用いた検討

  松浦 敬憲, 上田 佳秀, 安部 政俊, 新岡 宏彦, 長原 一, 小松 昇平, 福本 巧, 児玉 裕三, 松本 知訓

  (一財)日本消化器病学会, Mar. 2024, 日本消化器病学会雑誌, 121(臨増総会) (臨増総会), A37 - A37, Japanese


• 当科におけるアルコール関連肝疾患の現状と治療成績

  吉田 竜太郎, 田村 証司, 山本 淳史, 蓬莱 亞矢, 松浦 敬憲, 塩見 優紀, 矢野 嘉彦, 上田 佳秀, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2024, 日本消化器病学会雑誌, 121(臨増総会) (臨増総会), A381 - A381, Japanese


• 急性腎傷害を合併し高度急性脂肪肝の臨床像を呈した急性肝不全の一例

  吉田 竜太郎, 田村 証司, 朝治 直紀, 山本 淳史, 蓬莱 亞矢, 松浦 敬憲, 南 晶洋, 塩見 優紀, 矢野 嘉彦, 上田 佳秀, 児玉 裕三

  日本消化器病学会-近畿支部, Jan. 2024, 日本消化器病学会近畿支部例会プログラム・抄録集, 120回, 103 - 103, Japanese


• 肝細胞癌再発に対するアテゾリズマブ・ベバシズマブ併用療法後にirAE筋炎およびirAE重症筋無力症を併発した1例

  田村 証司, 吉田 竜太郎, 山本 淳史, 松浦 敬憲, 蓬莱 亞矢, 矢野 嘉彦, 上田 佳秀, 児玉 裕三

  日本消化器病学会-近畿支部, Jan. 2024, 日本消化器病学会近畿支部例会プログラム・抄録集, 120回, 104 - 104, Japanese


• 肝細胞癌アテゾリズマブ・ベバシズマブ併用療法におけるNLRの意義

  矢野 嘉彦, 山本 淳史, 吉田 竜太郎, 朝治 直紀, 井上 裕太, 河野 未樹, 蓬莱 亞矢, 松浦 敬憲, 塩見 優紀, 南 晶洋, 小松 昇平, 上田 佳秀, 児玉 裕三

  (一社)日本肝臓学会, Oct. 2023, 肝臓, 64(Suppl.3) (Suppl.3), A868 - A868, Japanese


• 肝細胞癌に対するデュルバルマブ・トレメリムマブ併用療法の治療経験から考える当院での薬物治療戦略

  山本 淳史, 田村 証司, 河野 未樹, 井上 裕太, 北代 準, 朝治 直紀, 吉田 竜太郎, 松浦 敬憲, 南 晶洋, 塩見 優紀, 矢野 嘉彦, 上田 佳秀, 児玉 裕三

  (一社)日本肝臓学会, Oct. 2023, 肝臓, 64(Suppl.3) (Suppl.3), A879 - A879, Japanese


• アルコール性肝癌の特徴と予後に関わる因子の検討

  矢野 嘉彦, 吉田 竜太郎, 山本 淳史, 蓬莱 亜矢, 朝治 直紀, 松浦 敬憲, 塩見 優紀, 南 晶洋, 上田 佳秀, 児玉 裕三

  (一社)日本肝臓学会, Oct. 2023, 肝臓, 64(Suppl.3) (Suppl.3), A888 - A888, Japanese


• 病理画像を用いたAIモデルによる肝細胞癌の多倍体化予測

  松浦 敬憲, 安部 政俊, 原田 宜幸, 木戸 正浩, 長原 一, 新岡 宏彦, 福本 巧, 上田 佳秀, 原 英二, 児玉 裕三, 松本 知訓

  (一財)日本消化器病学会, Oct. 2023, 日本消化器病学会雑誌, 120(臨増大会) (臨増大会), A817 - A817, Japanese


• 臨床検査情報システムを利用したウイルス肝炎患者の洗い出し

  矢野 嘉彦, 朝治 直紀, 吉田 竜太郎, 山本 淳史, 松浦 敬憲, 南 晶洋, 塩見 優紀, 上田 佳秀, 児玉 裕三

  (一社)日本肝臓学会, Sep. 2023, 肝臓, 64(Suppl.2) (Suppl.2), A633 - A633, Japanese


• C型肝硬変および肝細胞癌治療後に発症し、胆嚢原発と考えられた血管肉腫の1例

  田村 証司, 矢野 嘉彦, 芦崎 理沙, 朝治 直紀, 山本 淳史, 吉田 竜太郎, 松浦 敬憲, 蓬莱 亞矢, 南 晶洋, 上田 佳秀, 児玉 裕三

  日本消化器病学会-近畿支部, Sep. 2023, 日本消化器病学会近畿支部例会プログラム・抄録集, 119回, 120 - 120, Japanese


• アルコール性肝硬変を背景にParvimonas micraによる化膿性脊椎炎が疑われた一例

  芦崎 理沙, 南 晶洋, 田村 証司, 朝治 直紀, 山本 淳史, 吉田 竜太郎, 松浦 敬憲, 蓬莱 亞矢, 塩見 優紀, 矢野 嘉彦, 上田 佳秀, 児玉 裕三

  日本消化器病学会-近畿支部, Sep. 2023, 日本消化器病学会近畿支部例会プログラム・抄録集, 119回, 120 - 120, Japanese


• 心膜横隔静脈を主排血路とした胃静脈瘤に対してバルーン閉塞下逆行性経静脈的塞栓術が奏功した1例

  朝治 直紀, 南 晶洋, 芦崎 理沙, 田村 証司, 山本 淳史, 吉田 竜太郎, 松浦 敬憲, 蓬莱 亞矢, 塩見 優紀, 矢野 嘉彦, 上田 佳秀, 児玉 裕三

  日本消化器病学会-近畿支部, Sep. 2023, 日本消化器病学会近畿支部例会プログラム・抄録集, 119回, 121 - 121, Japanese


• COVID-19罹患後に急性発症型自己免疫性肝炎を発症し肝不全に至った一例

  河野 未樹, 山本 淳史, 芦崎 理沙, 田村 証司, 井上 裕太, 北代 隼, 朝治 直紀, 吉田 竜太郎, 松浦 敬憲, 蓬莱 亞矢, 南 晶洋, 塩見 優紀, 矢野 嘉彦, 上田 佳秀, 児玉 裕三

  日本消化器病学会-近畿支部, Sep. 2023, 日本消化器病学会近畿支部例会プログラム・抄録集, 119回, 121 - 121, Japanese


• HPVステータスの違いに規定される中咽頭癌細胞特性の比較検討(Comparative analysis of the characteristics of oropharyngeal cancer affected by HPV status)

  林 計企, 松本 知訓, 原田 宜幸, 松浦 敬憲, 鈴木 雅美, 福角 隆仁, 猪原 秀典, 原 英二

  (一社)日本癌学会, Sep. 2023, 日本癌学会総会記事, 82回, 1086 - 1086, English


• 肝細胞癌におけるゲノム多倍体化は,腫瘍の高悪性度を予測する(Genome doubling determines a characteristic subset of hepatocellular carcinoma with aggressive features)

  松浦 敬憲, 上田 佳秀, 原田 宜幸, 林 計企, 矢野 嘉彦, 宗 慎一, 木戸 正浩, 福本 巧, 児玉 裕三, 原 英二, 松本 知訓

  (一社)日本癌学会, Sep. 2023, 日本癌学会総会記事, 82回, 1597 - 1597, English


• 肝細胞癌に対するアテゾリズマブ・ベバシズマブ併用治療の治療効果に関わる因子と非奏功例の検討

  矢野 嘉彦, 山本 淳史, 安冨 栄一郎, 朝治 直紀, 吉田 竜太郎, 松浦 敬憲, 塩見 優紀, 南 晶洋, 上田 佳秀, 児玉 裕三

  (一社)日本肝臓学会, Apr. 2023, 肝臓, 64(Suppl.1) (Suppl.1), A384 - A384, Japanese


• ヒト肝細胞癌における多倍体化の臨床病理学的検討と評価法の開発

  松浦 敬憲, 上田 佳秀, 松本 知訓, 河野 未樹, 矢野 嘉彦, 児玉 裕三

  (一社)日本肝臓学会, Apr. 2023, 肝臓, 64(Suppl.1) (Suppl.1), A396 - A396, Japanese


• B型肝炎再活性化予防目的の核酸アナログ製剤使用例の検討

  矢野 嘉彦, 安冨 栄一郎, 山本 淳史, 朝治 直紀, 吉田 竜太郎, 松浦 敬憲, 塩見 優紀, 南 晶洋, 上田 佳秀, 児玉 裕三

  (一社)日本肝臓学会, Apr. 2023, 肝臓, 64(Suppl.1) (Suppl.1), A450 - A450, Japanese


• 当院の門脈圧亢進症に対する内視鏡治療およびIVRの検討

  朝治 直紀, 井上 裕太, 河野 未樹, 山本 淳史, 吉田 竜太郎, 安冨 栄一郎, 松浦 敬憲, 南 晶洋, 塩見 優紀, 矢野 嘉彦

  (一財)日本消化器病学会, Mar. 2023, 日本消化器病学会雑誌, 120(臨増総会) (臨増総会), A414 - A414, Japanese


• 異所・異時性に出現し,免疫組織学的に異なる特徴を示した肝細胞腺腫の一例

  吉田 竜太郎, 南 晶洋, 河野 未樹, 井上 裕太, 北代 隼, 朝治 直紀, 山本 淳史, 安冨 栄一郎, 松浦 敬憲, 塩見 優紀, 矢野 嘉彦, 上田 佳秀, 児玉 裕三

  (一社)日本肝臓学会, Oct. 2022, 肝臓, 63(Suppl.3) (Suppl.3), A761 - A761, Japanese


• COVID-19ワクチン接種後に出現した肝障害の一例

  朝治 直紀, 安冨 栄一郎, 井上 裕太, 河野 未樹, 北代 隼, 山本 淳史, 吉田 竜太郎, 松浦 敬憲, 南 晶洋, 塩見 優紀, 矢野 嘉彦, 上田 佳秀, 伊藤 智雄, 児玉 裕三

  日本消化器病学会-近畿支部, Oct. 2022, 日本消化器病学会近畿支部例会プログラム・抄録集, 117回, 106 - 106, Japanese


• 抗凝固療法中の肝細胞癌に対するアテゾリズマブ・ベバシズマブ併用療法中に発症した脳出血の一例

  安冨 栄一郎, 矢野 嘉彦, 山本 淳史, 北代 隼, 朝治 直紀, 吉田 竜太郎, 畑澤 友里, 松浦 敬憲, 塩見 優紀, 上田 佳秀, 児玉 裕三

  (一社)日本肝臓学会, Jun. 2022, 肝臓, 63(6) (6), 297 - 300, Japanese


• 進行肝細胞癌に対する分子標的治療の後治療の意義

  矢野 嘉彦, 吉田 竜太郎, 朝治 直紀, 山本 淳史, 松浦 敬憲, 塩見 優紀, 安冨 栄一郎, 畑澤 友里, 上田 佳秀, 児玉 裕三

  (一社)日本肝臓学会, Apr. 2022, 肝臓, 63(Suppl.1) (Suppl.1), A304 - A304, Japanese


• 脂肪肝モデルマウスに対する4型レジスタントスターチ投与による脂肪肝抑制効果の検討

  吉田 竜太郎, 矢野 嘉彦, 上田 佳秀, 朝治 直紀, 山本 淳史, 安冨 栄一郎, 畑澤 友里, 松浦 敬憲, 塩見 優紀, 児玉 裕三

  (一社)日本肝臓学会, Apr. 2022, 肝臓, 63(Suppl.1) (Suppl.1), A310 - A310, Japanese


• 慢性B型肝炎に対する核酸アナログ製剤使用の現状と長期経過

  矢野 嘉彦, 松浦 敬憲, 吉田 竜太郎, 朝治 直紀, 山本 淳史, 安冨 栄一郎, 畑澤 友里, 塩見 優紀, 上田 佳秀, 児玉 裕三

  (一社)日本肝臓学会, Apr. 2022, 肝臓, 63(Suppl.1) (Suppl.1), A413 - A413, Japanese


• 肝細胞癌に対するアテゾリズマブ+ベバシズマブ療法中にC型肝炎ウイルス減少と肝炎活動性低下を認めた一例

  徳永 貴史, 上田 佳秀, 北代 隼, 山本 淳史, 安冨 栄一郎, 畑澤 有里, 松浦 敬憲, 塩見 優紀, 矢野 嘉彦, 児玉 裕三

  日本消化器病学会-近畿支部, Feb. 2022, 日本消化器病学会近畿支部例会プログラム・抄録集, 116回, 127 - 127, Japanese


• 当院における急性肝不全に対する治療成績

  山本 淳史, 上田 佳秀, 蔵満 薫, 矢野 嘉彦, 安冨 栄一郎, 畑澤 友里, 松浦 敬憲, 塩見 優紀, 吉田 竜太郎, 朝治 直紀, 木戸 正浩, 福本 巧, 児玉 裕三

  (一社)日本門脈圧亢進症学会, Aug. 2021, 日本門脈圧亢進症学会雑誌, 27(3) (3), 177 - 177, Japanese


• 悪性胆道狭窄に対しfully covered SEMSを留置後、ステント内を穿通し胆道出血を来した仮性動脈瘤の一例

  島津 薫子, 山中 広大, 新丸 尚輝, 坂根 達哉, 松井 恒樹, 原 和也, 松浦 敬憲, 河原 史明, 三村 美津子, 南 晶洋, 西岡 千晴

  日本消化器内視鏡学会-近畿支部, Dec. 2020, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 105回, 70 - 70, Japanese


• 閉塞性黄疸で発見された肺低分化扁平上皮癌十二指腸転移の一例

  坂根 達哉, 河原 史明, 原 和也, 新丸 尚輝, 松井 恒樹, 山中 広大, 松浦 敬憲, 南 晶洋, 三村 美津子, 西岡 千晴

  日本消化器内視鏡学会-近畿支部, Dec. 2020, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 105回, 72 - 72, Japanese


• 診断と治療に苦慮したのちPOEMによる症状寛解を得たEGJOOとIEMの併存症例

  河原 史明, 田中 心和, 安丸 正一, 山中 広大, 松浦 敬憲, 南 晶洋, 阪口 博哉, 阿部 洋文, 西岡 千晴

  (NPO)日本食道学会, Dec. 2020, 日本食道学会学術集会プログラム・抄録集, 74回, 240 - 240, Japanese


• 膵胆管合流異常症(胆管非拡張型)の胆嚢摘出後、長期間経過後に胆管癌を発症した1例

  坂根 達哉, 山中 広大, 新丸 尚樹, 松井 恒樹, 原 和也, 松浦 敬憲, 河原 史明, 三村 美津子, 南 晶洋, 西岡 千晴

  日本消化器病学会-近畿支部, Oct. 2020, 日本消化器病学会近畿支部例会プログラム・抄録集, 113回, 105 - 105, Japanese


• 混合型IPMNと鑑別を要した十二指腸乳頭部癌とHigh-grade PanIN病変を併存した1例

  後藤 直大, 山崎 隆, 松浦 敬憲, 川島 龍樹, 古出 隆大, 安田 貴志, 藤田 敏忠, 千堂 宏義, 河原 啓, 具 英成

  (一社)日本胆道学会, Aug. 2020, 胆道, 34(3) (3), 609 - 609, Japanese


• 浸潤性膵管癌と術前診断した膵体部Highgrade PanINの1切除例

  後藤 直大, 山崎 隆, 松浦 敬憲, 山中 広大, 川島 龍樹, 古出 隆大, 安田 貴志, 藤田 敏忠, 千堂 宏義, 宮下 勝, 具 英成

  (一社)日本膵臓学会, Jul. 2020, 膵臓, 35(3) (3), A453 - A453, Japanese


• 除菌治療で奏効し得なかったMALTリンパ腫にたいして放射線療法を行った1例

  新丸 尚輝, 河原 史明, 坂根 達哉, 松井 恒樹, 山中 広大, 松浦 敬憲, 三村 美津子, 南 晶洋, 谷 聡, 西岡 千晴

  日本消化器内視鏡学会-近畿支部, Jun. 2020, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 104回, 68 - 68, Japanese


• 【日常診療で接する薬剤性皮膚障害】(Part4.)OTC/サプリメント/漢方による薬疹(case11) 市販総合感冒薬による中毒性表皮壊死症を契機に発症した胆管消失症候群の1例

  山野 希, 全 陽, 井上 友介, 松浦 敬憲, 下浦 真一, 足立 厚子

  (株)Gakken, Jan. 2020, Visual Dermatology, 19(2) (2), 191 - 193, Japanese


• 血清IgG4の著明な上昇を来たした自己免疫性肝炎の一例

  松浦 敬憲, 南 晶洋, 谷 聡

  (一社)日本肝臓学会, Nov. 2019, 肝臓, 60(Suppl.3) (Suppl.3), A889 - A889, Japanese


• 術前診断が可能であった1mm大の早期十二指腸乳頭部癌の1手術例

  後藤 直大, 山崎 隆, 松浦 敬憲, 古出 隆大, 安田 貴志, 千堂 宏義, 村松 三四郎, 宮下 勝, 具 英成

  (一社)日本胆道学会, Oct. 2019, 胆道, 33(3) (3), 662 - 662, Japanese


• 膵癌術後再発による急性輸入脚閉塞症に対して内視鏡下消化管ステント留置が有用であった一例

  原田 彩香, 松浦 敬憲, 首藤 彰, 河原 史明, 南 晶洋, 三村 美津子, 谷 聡

  日本消化器病学会-近畿支部, Oct. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111回, 91 - 91, Japanese


• 膵周囲膿瘍ドレーンの胃穿破により生じた瘻孔に対し、OTSCに加えてPGAシートを併用するも閉鎖に難渋した1例

  河原 史明, 南 晶洋, 千堂 宏義, 松浦 敬憲, 谷 聡, 具 英成

  (一社)日本消化器内視鏡学会, May 2019, Gastroenterological Endoscopy, 61(Suppl.1) (Suppl.1), 1018 - 1018, Japanese


• サテライト病院としての経口内視鏡的筋層切開術(POEM)導入における治療成績

  河原 史明, 南 晶洋, 松井 恒樹, 首藤 彰, 松浦 敬憲, 福永 馨, 谷 聡, 阪口 博哉, 阿部 洋文, 有吉 隆佑, 田中 心和, 具 英成

  (一財)日本消化器病学会, Mar. 2019, 日本消化器病学会雑誌, 116(臨増総会) (臨増総会), A276 - A276, Japanese


• 胃瘻増設部への病巣播種が疑われた胸部下部食道癌の一例

  西山 美菜子, 南 晶洋, 首藤 彰, 松浦 敬憲, 河原 史明, 安田 貴志, 高山 恵津子, 谷 聡, 山崎 隆

  日本消化器病学会-近畿支部, Feb. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 110回, 97 - 97, Japanese


• 当院における高齢C型肝炎患者に対するに対するIFNフリーDAA治療の長期予後の検討

  廣畑 成也, 渡部 貴文, 松浦 敬憲, 白川 裕, 戎谷 力, さか本 喜雄, 尹 聖哲

  (一財)日本消化器病学会, Oct. 2018, 日本消化器病学会雑誌, 115(臨増大会) (臨増大会), A736 - A736, Japanese


• Serotype,Genotypeの判定不能および両者の不一致例におけるDAA療法

  尹 聖哲, 渡部 貴文, 松浦 敬憲, 白川 裕, 戎谷 力, さか本 喜雄, 廣畑 成也

  (一社)日本肝臓学会, Sep. 2018, 肝臓, 59(Suppl.2) (Suppl.2), A705 - A705, Japanese


• 抗ウイルス治療例における再感染リスクの高い感染経路の集団の検討

  尹 聖哲, 廣畑 成也, 松浦 敬憲

  (一社)日本肝臓学会, Apr. 2018, 肝臓, 59(Suppl.1) (Suppl.1), A470 - A470, Japanese


• 市販総合感冒薬による中毒性表皮壊死症を契機に発症した胆管消失症候群

  山野 希, 井上 友介, 白井 成鎬, 足立 厚子, 松浦 敬憲, 全 陽, 下浦 真一

  日本皮膚科学会-大阪地方会・京滋地方会, Apr. 2018, 皮膚の科学, 17(2) (2), 119 - 119, Japanese


• ゲノタイプ3型の臨床像と抗ウイルス療法の検討

  尹 聖哲, 廣畑 成也, 松浦 敬憲, 白川 裕, 戎谷 力, さか本 喜雄, 渡部 貴文

  (一財)日本消化器病学会, Mar. 2018, 日本消化器病学会雑誌, 115(臨増総会) (臨増総会), A308 - A308, Japanese


• 当院におけるgenotype1型の透析中C型慢性肝炎・代償性肝硬変に対するDAA療法の検討 肝生検による線維化の評価を含めて

  廣畑 成也, 渡部 貴文, 松浦 敬憲, 白川 裕, 戎谷 力, さか本 喜雄, 尹 聖哲

  (一社)日本肝臓学会, Nov. 2017, 肝臓, 58(Suppl.3) (Suppl.3), A795 - A795, Japanese


• 抗ウイルス療法にてSVRとなるも再感染した感染高危険集団のC型肝炎4例

  尹 聖哲, 廣畑 成也, 松浦 敬憲, 白川 裕, 戎谷 力, さか本 喜雄, 渡部 貴文

  (一社)日本肝臓学会, Nov. 2017, 肝臓, 58(Suppl.3) (Suppl.3), A873 - A873, Japanese


• 高度の黄疸を呈した後自然治癒を認めたC型急性肝炎の1例 宿主免疫の検討を加えて

  渡部 貴文, 松浦 敬憲, 白川 裕, 戎谷 力, さか本 喜雄, 廣畑 成也, 尹 聖哲

  (一社)日本肝臓学会, Nov. 2017, 肝臓, 58(Suppl.3) (Suppl.3), A954 - A954, Japanese


• ウイルス制御を目指したB型肝炎の治療戦略 核酸アナログ投与例と非活動性キャリアにおけるHBsAgとHBcrAgの推移と肝発癌に関する検討

  尹 聖哲, 廣畑 成也, 松浦 敬憲

  (一社)日本肝臓学会, Apr. 2017, 肝臓, 58(Suppl.1) (Suppl.1), A80 - A80, Japanese


• 当院におけるC型慢性肝炎、代償性肝硬変に対する経口抗ウイルス療法後の肝発癌の現状

  廣畑 成也, 尹 聖哲, 松浦 敬憲, 白川 裕, 戎谷 力, さか本 喜雄

  (一社)日本肝臓学会, Apr. 2017, 肝臓, 58(Suppl.1) (Suppl.1), A436 - A436, Japanese


• 大腸アニサキス症の1例

  東田 歩, 伊崎 健太, 西岡 瑛子, 酒井 英郎, 小川 恭弘, 松浦 敬憲

  金原出版(株), Mar. 2017, 臨床放射線, 62(3) (3), 441 - 444, Japanese


• 当院における既存のDAA療法と比較したOBV/PTV/r療法の成績

  松浦 敬憲, 尹 聖哲, 廣畑 成也, 渡部 貴文, 白川 裕, 戎谷 力, さか本 喜雄

  (一財)日本消化器病学会, Mar. 2017, 日本消化器病学会雑誌, 114(臨増総会) (臨増総会), A365 - A365, Japanese


• 肝生検を併用したDAA療法導入前の肝発癌リスク評価

  尹 聖哲, 廣畑 成也, 松浦 敬憲, 白川 裕, 戎谷 力, さか本 喜雄

  (一財)日本消化器病学会, Mar. 2017, 日本消化器病学会雑誌, 114(臨増総会) (臨増総会), A367 - A367, Japanese


• 腎障害を有するGenotype1型C型慢性肝炎・代償性肝硬変に対するDAA療法の有効性と安全性の検討

  廣畑 成也, 尹 聖哲, 松浦 敬憲, 渡部 貴文, 白川 裕, 戎谷 力, さか本 喜雄

  (一財)日本消化器病学会, Mar. 2017, 日本消化器病学会雑誌, 114(臨増総会) (臨増総会), A386 - A386, Japanese


• IFNフリーDAA療法はIFNベースの治療と同様に長期予後を改善するか

  尹 聖哲, 廣畑 成也, 松浦 敬憲, 白川 裕, さか本 喜雄, 堀田 和亜

  (一社)日本肝臓学会, Sep. 2016, 肝臓, 57(Suppl.2) (Suppl.2), A545 - A545, Japanese


• 当院におけるC型慢性肝炎・代償性肝硬変に対するSOF/LDVおよびSOF/RBV併用療法の治療成績

  廣畑 成也, 尹 聖哲, 松浦 敬憲, 白川 裕, さか本 喜雄, 堀田 和亜

  (一社)日本肝臓学会, Sep. 2016, 肝臓, 57(Suppl.2) (Suppl.2), A572 - A572, Japanese


• 複数回の門脈大循環短絡路塞栓により制御し得た猪瀬型肝性脳症の1例

  西岡 瑛子, 伊崎 健太, 東田 歩, 酒井 英郎, 小川 恭弘, 松浦 敬憲, 大竹 啓夫, 杉本 幸司

  (一社)日本インターベンショナルラジオロジー学会, Aug. 2016, IVR: Interventional Radiology, 31(3) (3), 263 - 263, Japanese


• IFNフリーDAA療法とIFN療法著効例における線維化と肝予備能の改善、肝発癌リスク低下についての比較検討

  尹 聖哲, 廣畑 成也, 松浦 敬憲, 白川 裕, さか本 喜雄, 堀田 和亜

  (一社)日本肝臓学会, Apr. 2016, 肝臓, 57(Suppl.1) (Suppl.1), A320 - A320, Japanese


• 当院における1型C型慢性肝炎・代償性肝硬変に対するソホスブビル/レジパスビル併用療法の初期治療成績

  廣畑 成也, 尹 聖哲, 松浦 敬憲, 白川 裕, さか本 喜雄, 堀田 和亜

  (一社)日本肝臓学会, Apr. 2016, 肝臓, 57(Suppl.1) (Suppl.1), A353 - A353, Japanese


• 当院におけるダクラタスビル/アスナプレビル併用療法の治療成績

  廣畑 成也, 尹 聖哲, 松浦 敬憲, 白川 裕, さか本 喜雄, 堀田 和亜

  (一財)日本消化器病学会, Mar. 2016, 日本消化器病学会雑誌, 113(臨増総会) (臨増総会), A350 - A350, Japanese


• 当院における2型C型慢性肝炎・代償性肝硬変に対するソホスブビル/リバビリン併用療法の初期治療成績

  松浦 敬憲, 廣畑 成也, 尹 聖哲, 白川 裕, さか本 喜雄, 堀田 和亜

  (一財)日本消化器病学会, Mar. 2016, 日本消化器病学会雑誌, 113(臨増総会) (臨増総会), A398 - A398, Japanese


• 肝様分化を有した大腸癌の1例

  西岡 瑛子, 伊崎 健太, 小川 泰弘, 松浦 敬憲, 常見 幸三, 藤本 昌代

  (公社)日本医学放射線学会, Feb. 2016, Japanese Journal of Radiology, 34(Suppl.) (Suppl.), 52 - 52, Japanese


• 当院における1型C型慢性肝炎に対するDAAs併用療法の治療成績

  廣畑 成也, 尹 聖哲, 松浦 敬憲, 白川 裕, さか本 喜雄, 堀田 和亜

  (一社)日本肝臓学会, Nov. 2015, 肝臓, 56(Suppl.3) (Suppl.3), A963 - A963, Japanese


• NS5A薬剤耐性を踏まえたダクラタスビル・アスナプレビル併用療法とシメプレビル3剤併用療法の治療適応と早期ウイルス効果の比較検討

  尹 聖哲, 廣畑 成也, 松浦 敬憲, 白川 裕, さか本 喜雄, 堀田 和亜, 矢野 嘉彦

  (一社)日本肝臓学会, Nov. 2015, 肝臓, 56(Suppl.3) (Suppl.3), A1017 - A1017, Japanese


• 当院におけるTolvaptan長期投与の適応について

  松浦 敬憲, 尹 聖哲, 廣畑 成也, 白川 裕, さか本 喜雄, 堀田 和亜

  (一社)日本肝臓学会, Nov. 2015, 肝臓, 56(Suppl.3) (Suppl.3), A1024 - A1024, Japanese


• 当院におけるシメプレビル3剤併用療法の治療成績

  廣畑 成也, 尹 聖哲, 松浦 敬憲, 白川 裕, さか本 喜雄, 堀田 和亜

  (一社)日本肝臓学会, Sep. 2015, 肝臓, 56(Suppl.2) (Suppl.2), A717 - A717, Japanese


• HCVNS3、NS5A領域の耐性変異からみたDAAs療法とIFN併用DAA療法の治療選択

  尹 聖哲, 廣畑 成也, 松浦 敬憲, 白川 裕, さか本 喜雄, 堀田 和亜, 矢野 嘉彦

  (一社)日本肝臓学会, Sep. 2015, 肝臓, 56(Suppl.2) (Suppl.2), A719 - A719, Japanese


• 当院でのTolvaptanを早期に投与した症例の検討

  松浦 敬憲, 廣畑 成也, 尹 聖哲, 白川 裕, さか本 喜雄, 堀田 和亜

  (一社)日本肝臓学会, Sep. 2015, 肝臓, 56(Suppl.2) (Suppl.2), A779 - A779, Japanese


• 大腸アニサキス症の1例

  東田 歩, 酒井 英郎, 西岡 瑛子, 伊崎 健太, 小川 恭弘, 松浦 敬憲

  (公社)日本医学放射線学会, Sep. 2015, 日本医学放射線学会秋季臨床大会抄録集, 51回, S478 - S479, Japanese


• HCV NS3、NS5A領域の変異とシメプレビル併用療法における抗ウイルス効果の検討

  尹 聖哲, 廣畑 成也, 松浦 敬憲, 白川 裕, さか本 喜雄, 堀田 和亜, 矢野 嘉彦

  (一社)日本肝臓学会, Apr. 2015, 肝臓, 56(Suppl.1) (Suppl.1), A246 - A246, Japanese


• シメプレビル3剤用療法の薬剤アドヒアランスの検討

  廣畑 成也, 尹 聖哲, 松浦 敬憲, 白川 裕, さか本 喜雄, 堀田 和亜

  (一社)日本肝臓学会, Apr. 2015, 肝臓, 56(Suppl.1) (Suppl.1), A479 - A479, Japanese


• 当院におけるシメプレビル3剤併用療法の治療効果の検討

  松浦 敬憲, 廣畑 成也, 尹 聖哲, 白川 裕, さか本 喜雄, 堀田 和亜

  (一社)日本肝臓学会, Apr. 2015, 肝臓, 56(Suppl.1) (Suppl.1), A486 - A486, Japanese


• 当院における総胆管結石に対する内視鏡的乳頭ラージバルーン拡張術の経験

  さか本 喜雄, 松浦 敬憲, 八幡 晋輔, 白川 裕, 大内 智子, 堀田 和亜, 廣畑 成也, 尹 聖哲

  (一社)日本消化器内視鏡学会, Sep. 2014, Gastroenterological Endoscopy, 56(Suppl.2) (Suppl.2), 3032 - 3032, Japanese


• B型慢性肝疾患の各病態と治療におけるHBsAg減少量と発癌リスク

  尹 聖哲, 廣畑 成也, 松浦 敬憲, 八幡 晋輔, 白川 裕, さか本 喜雄, 堀田 和亜, 大内 佐智子

  (一社)日本肝臓学会, Sep. 2014, 肝臓, 55(Suppl.2) (Suppl.2), A589 - A589, Japanese


• シメプレビル3剤併用療法の初期治療効果と副作用の検討 テラプレビル3剤併用療法との比較

  廣畑 成也, 尹 聖哲, 松浦 敬憲, 大内 佐智子, 八幡 晋輔, 白川 裕, さか本 善雄, 堀田 和亜

  (一社)日本肝臓学会, Sep. 2014, 肝臓, 55(Suppl.2) (Suppl.2), A666 - A666, Japanese


• 肝性浮腫に対する当院でのTolvaptan投与症例の検討

  松浦 敬憲, 尹 聖哲, 八幡 晋輔, 白川 裕, さか本 喜雄, 大内 佐智子, 堀田 和亜, 廣畑 成也

  (一社)日本肝臓学会, Sep. 2014, 肝臓, 55(Suppl.2) (Suppl.2), A669 - A669, Japanese


• 自己免疫性肝炎における再燃例の特徴

  八幡 晋輔, 松浦 敬憲, 白川 裕, さか本 喜雄, 大内 佐智子, 堀田 和亜, 廣畑 成也, 尹 聖哲

  (一社)日本肝臓学会, Sep. 2014, 肝臓, 55(Suppl.2) (Suppl.2), A677 - A677, Japanese


• C型肝炎治療の病診連携パスにおける高齢者の問題点と展望

  尹 聖哲, 松浦 敬憲, 八幡 晋輔, 白川 裕, さか本 喜雄, 大内 佐智子, 堀田 和亜, 廣畑 成也

  (一社)日本肝臓学会, Apr. 2014, 肝臓, 55(Suppl.1) (Suppl.1), A345 - A345, Japanese


• IIc様形態を示した限局型胃アミロイドーシスの1例

  さか本 喜雄, 松浦 敬憲, 八幡 晋輔, 白川 裕, 大内 佐智子, 堀田 和亜, 廣畑 成也, 尹 聖哲

  (一社)日本消化器内視鏡学会, Apr. 2014, Gastroenterological Endoscopy, 56(Suppl.1) (Suppl.1), 1298 - 1298, Japanese


• TVR/peg-IFN/RBV併用法におけるTVR至適投与量の検討

  松浦 敬憲, 尹 聖哲, 廣畑 成也, 大内 佐智子, 八幡 晋輔, 白川 裕, さか本 喜雄, 堀田 和亜

  (一財)日本消化器病学会, Mar. 2014, 日本消化器病学会雑誌, 111(臨増総会) (臨増総会), A306 - A306, Japanese


• 当院で経験した潰瘍性大腸炎における5-ASA製剤の副作用

  大内 佐智子, 松浦 敬憲, 廣畑 成也, さか本 喜雄, 堀田 和亜, 八幡 晋輔, 白川 裕, 尹 聖哲, 山内 健史

  (一財)日本消化器病学会, Mar. 2014, 日本消化器病学会雑誌, 111(臨増総会) (臨増総会), A318 - A318, Japanese


• B型慢性肝疾患における核酸アナログ投与例のHBsAg減少量に関連する因子

  尹 聖哲, 廣畑 成也, 大内 佐智子, 松浦 敬憲, 八幡 晋輔, 白川 裕, さか本 喜雄, 堀田 和亜

  (一財)日本消化器病学会, Mar. 2014, 日本消化器病学会雑誌, 111(臨増総会) (臨増総会), A335 - A335, Japanese


• ソラフェニブ投与により消化管毛細血管拡張症を発症したと考えられた進行肝細胞癌の3例

  廣畑 成也, 白川 裕, 尹 聖哲, 松浦 敬憲, 八幡 晋輔, さか本 喜雄, 大内 佐智子, 堀田 和亜

  (一財)日本消化器病学会, Mar. 2014, 日本消化器病学会雑誌, 111(臨増総会) (臨増総会), A366 - A366, Japanese


• 40歳台で診断されたWilson病の兄弟

  八幡 晋輔, 松浦 敬憲, 白川 裕, さか本 喜雄, 大内 佐智子, 堀田 和亜, 廣畑 成也, 尹 聖哲, 服部 亜衣, 林 久男, 原田 大

  (一社)日本肝臓学会, Nov. 2013, 肝臓, 54(Suppl.3) (Suppl.3), A870 - A870, Japanese


• 慢性C型肝炎に対するTelaprevir/PegIFN/RBV併用療法中に免疫性血小板減少性紫斑病(ITP)を含む多彩な副作用を呈した1例

  松浦 敬憲, 八幡 晋輔, 白川 裕, さか本 喜雄, 大内 佐智子, 堀田 和亜, 廣畑 成也, 尹 聖哲

  (一社)日本肝臓学会, Nov. 2013, 肝臓, 54(Suppl.3) (Suppl.3), A889 - A889, Japanese


• ラミブジン耐性株出現後アデホビル併用投与中にHBs抗原が陰性化した若年男性B型慢性肝炎の1例

  尹 聖哲, 松浦 敬憲, 八幡 晋輔, 白川 裕, さか本 喜雄, 大内 佐智子, 堀田 和亜, 廣畑 成也

  (一社)日本肝臓学会, Nov. 2013, 肝臓, 54(Suppl.3) (Suppl.3), A903 - A903, Japanese


• 直腸Ra部に発生した腺扁平上皮癌の1例

  多代 尚広, 高原 秀典, 松浦 敬憲

  日本臨床外科学会, Oct. 2010, 日本臨床外科学会雑誌, 71(増刊) (増刊), 658 - 658, Japanese


• 当院における消化器がん発見に至る検診の役割

  小野 成樹, 松浦 敬憲, 田渕 幹康, 三井 康裕, 勝谷 誠, 高尾 雄二郎

  (公社)日本人間ドック・予防医療学会, Aug. 2010, 人間ドック, 25(2) (2), 444 - 444, Japanese


• 膵癌におけるFDG-PET診断

  上 和広, 土井 隆一郎, 松浦 敬憲, 森田 成彦, 長井 和之, 小泉 将之, 増井 俊彦, 川口 義弥, 上本 伸二

  日本臨床外科学会, Oct. 2009, 日本臨床外科学会雑誌, 70(増刊) (増刊), 441 - 441, Japanese


• 本態性血小板血症を伴う下部胆管癌に対して幽門輪温存膵頭十二指腸切除術を施行した一例

  松浦 敬憲, 上 和広, 森田 成彦, 田邊 和孝, 末次 弘実, 高原 秀典, 横山 正, 實光 章, 邊見 公雄

  日本臨床外科学会, Oct. 2009, 日本臨床外科学会雑誌, 70(増刊) (増刊), 791 - 791, Japanese


• 慢性B型肝炎を伴う特発性食道破裂の1例

  森田 成彦, 上 和広, 松浦 敬憲, 田邊 和孝, 末次 弘実, 高原 秀典, 横山 正, 實光 章, 邊見 公雄

  日本臨床外科学会, Oct. 2009, 日本臨床外科学会雑誌, 70(増刊) (増刊), 970 - 970, Japanese


• 外陰部に皮膚浸潤した子宮頸癌再発患者に対しMohs' pasteを使用した緩和治療の経験

  東田 太郎, 森田 成彦, 松浦 敬憲, 黄 豊羽, 常盤 洋一, 末次 弘美, 柴岡 秀人, 村上 賢一郎, 大井 克之

  (一社)日本癌治療学会, Sep. 2009, 日本癌治療学会誌, 44(2) (2), 843 - 843, Japanese


• 難治性皮膚瘻を呈した膿腎症の一例

  松浦 敬憲, 高原 秀典, 中村 公治郎, 上 和広, 實光 章, 邉見 公雄

  日本臨床外科学会, Oct. 2008, 日本臨床外科学会雑誌, 69(増刊) (増刊), 696 - 696, Japanese

• Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma.

  Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Teruki Miyake, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Takanori Matsuura, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  Journal of gastroenterology, Aug. 2025, English, BACKGROUND: Immune-mediated adverse events (imAEs) are a significant concern in patients with unresectable hepatocellular carcinoma (uHCC) undergoing combination immunotherapy with durvalumab and tremelimumab (Dur/Tre). This study aimed to investigate the potential association of risk factors, particularly nutrition and immune markers, associated with the development of imAEs. METHODS: Between November 2022 and December 2024, 312 patients with uHCC treated with Dur/Tre were enrolled and retrospectively analyzed. Clinical characteristics, inflammatory markers, and nutritional indices (Geriatric Nutritional Risk Index [GNRI], body mass index, Prognostic Nutritional Index-Onodera, C-reactive protein-to-albumin ratio, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio) were evaluated to identify predictors for imAE development. RESULTS: The imAEs occurred in 122 patients (39.1%), most commonly affecting dermatological, gastrointestinal, and endocrine systems. On multivariate analysis, only normal GNRI (≥ 98) was independently associated with a higher incidence of imAE (odds ratio: 1.99, 95% confidence interval: 1.05-3.79, P = 0.036). Patients with GNRI ≥ 98 also showed better overall survival (OS) than those with GNRI < 98 (not reached vs. 12.5 months, P < 0.001). Among patients who developed imAEs, no significant differences were observed in the imAE types or high-dose steroid use between the GNRI ≥ 98 group (n = 66) and the GNRI < 98 group (n = 56) (40.9% vs. 58.9%, P = 0.069). CONCLUSIONS: Normal GNRI status (≥ 98) was associated with an increased risk of imAE development and improved OS in patients with uHCC receiving Dur/Tre therapy. GNRI may be a useful clinical factor for identifying patients at higher risk of developing imAEs.


• Utilizing the Conversion Concept Based on Disease Status Following Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma

  Shohei Komatsu, Toshifumi Tada, Kazuki Terashima, Nobuaki Ishihara, Masaki Omori, Takanori Matsuura, Eisuke Ueshima, Keitaro Sofue, Yuzo Kodama, Takumi Fukumoto

  World Journal of Surgery, Aug. 2025


• Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis.

  Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hidenao Noritake, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takashi Nishimura, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Hideyuki Tamai, Takanori Matsuura, Shohei Komatsu, Yoshihide Ueda, Yoshiko Nakamura, Osamu Yoshida, Kosuke Matsui, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo

  Hepatology research : the official journal of the Japan Society of Hepatology, Aug. 2025, English, AIM: To evaluate the safety and efficacy of durvalumab plus tremelimumab (Dur/Tre) in older adults with unresectable hepatocellular carcinoma (HCC). METHODS: A total of 345 patients with HCC who received Dur/Tre were included in this study. Using propensity score matching, we compared outcomes between older (aged ≥ 75 years; n = 120) and younger individuals (n = 120). RESULTS: The median progression-free survival (PFS) was 3.3 months in the older group and 4.5 months in the younger group (p = 0.271). The median overall survival (OS) was 17.0 months in older individuals and 19.2 months in younger individuals (p = 0.598). No statistically significant differences were observed in the therapeutic response between the two groups (p = 0.264). Additionally, the incidence of immune-mediated adverse events (AEs) did not differ significantly between older and younger individuals. Multivariate analyses revealed that age group (older vs. younger) was not an independent prognostic factor for PFS (p = 0.250) or OS (p = 0.489). In a subgroup analysis stratifying older individuals into three age categories (75-79, 80-84, and ≥ 85 years), no significant differences were observed in the cumulative OS or PFS across the subgroups (p = 0.308 and 0.783). Similarly, the incidence of immune-mediated AEs did not differ significantly among the age categories. CONCLUSIONS: Dur/Tre appears to be a safe and effective treatment option for patients with HCC, regardless of age. Dur/Tre appears to be a safe and effective treatment option for patients with unresectable HCC, regardless of age.


• Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab.

  Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takashi Nishimura, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Hideyuki Tamai, Takanori Matsuura, Shohei Komatsu, Yoshihide Ueda, Yoshiko Nakamura, Osamu Yoshida, Kosuke Matsui, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo

  Liver international : official journal of the International Association for the Study of the Liver, Aug. 2025, English, BACKGROUND AND AIMS: To assess the outcomes of patients with hepatocellular carcinoma (HCC) who were treated with atezolizumab plus bevacizumab (Atezo/Bev), categorised by oncological resectability criteria, which reflect tumour burden and extent of disease. METHODS: A cohort of 467 HCC patients who received Atezo/Bev was enrolled. Patients were classified into two groups based on oncological resectability criteria: BR (borderline resectable) 1 (n = 153) and BR2 (n = 314). RESULTS: The median progression-free survival (PFS) was 9.0 months in the BR1 group and 6.8 months in the BR2 group (p = 0.014). Multivariable analysis identified the following independent prognostic factors for PFS: age ≥ 75 years (hazard ratio [HR], 1.309), albumin-bilirubin (ALBI) grade ≥ 2 (HR, 1.494), neutrophil-to-lymphocyte ratio (NLR) ≥ 3 (HR, 1.289), α-fetoprotein ≥ 100 ng/mL (HR, 1.523) and BR2 classification (HR, 1.360). The median overall survival (OS) was 25.3 months in the BR1 group and 22.3 months in the BR2 group (p = 0.048). Multivariable analysis identified the following independent prognostic factors for OS: age ≥ 75 years (HR, 1.522), ALBI grade ≥ 2 (HR, 2.411), NLR ≥ 3 (HR, 1.635), α-fetoprotein ≥ 100 ng/mL (HR, 1.530) and BR2 classification (HR, 1.421). When oncological resectability factors (tumour number and size, vascular invasion and extrahepatic spread) were incorporated into the multivariable analysis, major vascular invasion emerged as a significant predictor of both PFS (HR, 3.188) and OS (HR, 2.650). CONCLUSIONS: In patients with HCC characterised by limited resectability undergoing Atezo/Bev, vascular invasion, in addition to liver function, is a critical prognostic determinant of tumour progression.


• Selective identification of polyploid hepatocellular carcinomas with poor prognosis by artificial intelligence-based pathological image recognition

  Takanori Matsuura, Masatoshi Abe, Yoshiyuki Harada, Masahiro Kido, Hajime Nagahara, Yuzo Kodama, Yoshihide Ueda, Eiji Hara, Hirohiko Niioka, Tomonori Matsumoto

  Communications Medicine, Jul. 2025


• Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.

  Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takashi Nishimura, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Hideyuki Tamai, Takanori Matsuura, Shohei Komatsu, Yoshihide Ueda, Yoshiko Nakamura, Osamu Yoshida, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo

  Hepatology research : the official journal of the Japan Society of Hepatology, Jun. 2025, English, AIM: To investigate the prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) on outcomes in patients with hepatocellular carcinoma (HCC) treated with durvalumab plus tremelimumab (Dur/Tre). METHODS: A total of 182 patients with HCC who received Dur/Tre were included in the analysis. Univariate and multivariate survival analyses were conducted. Additionally, hazard ratio (HR) spline curve analysis was used to determine the optimal NLR cut-off values for predicting overall survival (OS). RESULTS: The median progression-free survival (PFS) was 3.5 months (95% confidence interval [CI]: 2.7-4.4), whereas the median OS was not reached (95% CI: 12.1 months-not reached). Multivariate analysis demonstrated that treatment with Dur/Tre as a second-line therapy or beyond was independently associated with worse PFS (HR: 1.819; 95% CI: 1.230-2.688; p = 0.003). Furthermore, an NLR of ≥ 2.56 was identified as an independent predictor of reduced OS (HR: 1.919; 95% CI: 1.033-3.566; p = 0.039). The median OS was not reached (95% CI: 12.3 months-not reached) in patients with an NLR of < 2.56, compared with 12.1 months (95% CI: 9.0 months-not reached) in those with an NLR of ≥ 2.56 (p = 0.016). A Sankey diagram illustrating post-treatment outcomes revealed that a significantly larger proportion of patients with high NLRs did not proceed to subsequent therapies but instead received best supportive care (p = 0.046). Spline curve analysis showed that an NLR range of approximately 2.3-3.0 represents an appropriate cut-off for predicting OS. CONCLUSIONS: The NLR is a significant prognostic biomarker for OS in patients with HCC treated with Dur/Tre.


• Prognosis of Hepatectomy versus Systemic Chemotherapy Based on Oncological Resectability Criteria for Borderline Resectable Hepatocellular Carcinoma.

  Shohei Komatsu, Toshifumi Tada, Takashi Nishimura, Motofumi Tanaka, Atsushi Takebe, Saeko Kushida, Yoshimi Fujishima, Nobuaki Ishihara, Takanori Matsuura, Ikuo Nakamura, Taro Okazaki, Masahiro Tsuda, Jun Ishida, Ippei Matsumoto, Seiko Hirono, Hirayuki Enomoto, Yuzo Kodama, Takumi Fukumoto

  Liver cancer, Jun. 2025, English, INTRODUCTION: Oncological resectability criteria for hepatocellular carcinoma have been defined (resectable [R]/borderline resectable 1 [BR1]/borderline resectable 2 [BR2]); however, their validation is necessary. METHODS: A total of 1,469 patients who underwent hepatectomy and 525 patients who received systemic chemotherapy, including lenvatinib, atezolizumab plus bevacizumab, and durvalumab plus tremelimumab, as first-line treatment were analyzed. RESULTS: In the BR1 group, the median survival times (MSTs) of patients who underwent hepatectomy and systemic chemotherapy were 52.7 and 34.6 months, respectively, without a significant difference (p = 0.075). In the propensity score matching (PSM) analysis of the BR1 group, the MSTs of hepatectomy and systemic chemotherapy were 42.4 and 35.1 months, respectively, without a significant difference (p = 0.772). Hepatitis virus infection, modified albumin-bilirubin (mALBI) grade 2b + 3, and the presence of extrahepatic metastasis were identified as poor prognostic factors for hepatectomy, whereas mALBI grade 2b + 3 was the only poor prognostic factor for systemic chemotherapy. In the BR2 group, the MSTs of hepatectomy and systemic chemotherapy were 20.1 and 19.5 months, respectively, with significantly better survival for hepatectomy than for systemic chemotherapy (p = 0.017). In the PSM analysis of the BR2 group, the MSTs of hepatectomy and systemic chemotherapy were 20.1 and 21.0 months, respectively, without a significant difference (p = 0.375). Serum alpha-fetoprotein levels≥100, intrahepatic tumor number ≥6, and the presence of extrahepatic metastasis were identified as poor prognostic factors for hepatectomy, whereas female, serum alpha-fetoprotein levels ≥100, mALBI grade 2b + 3, intrahepatic maximal tumor size >5 cm, and the presence of extrahepatic metastasis were identified as poor prognostic factors for systemic chemotherapy. CONCLUSION: In the PSM analysis, no significant differences were observed between the BR1 and BR2 groups for hepatectomy and systemic chemotherapy. The intrahepatic tumor number for hepatectomy and the intrahepatic maximal tumor size for systemic chemotherapy are significant risk factors for BR2 patients, highlighting the characteristics of each treatment and the potential for selecting the optimal modality.


• Development of a Predictive Model for Classifying Immune Checkpoint Inhibitor-Induced Liver Injury Types.

  Jun Kitadai, Toshifumi Tada, Takanori Matsuura, Mayumi Ehara, Tatsuya Sakane, Miki Kawano, Yuta Inoue, Shoji Tamura, Aya Horai, Yuuki Shiomi, Yoshihiko Yano, Yuzo Kodama

  JGH open : an open access journal of gastroenterology and hepatology, Apr. 2025, English, AIMS: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; however, they are associated with ICI-induced liver injury (ICI-LI), which manifests as hepatocellular, mixed, or cholestatic patterns with variable treatment responses. This study aimed to develop and validate a predictive model to identify ICI-LI type using clinical data available at ICI initiation. METHODS: A retrospective analysis of 297 patients with ICI-LI was conducted. Baseline clinical data were analyzed using univariate and multivariate logistic regression to predict ICI-LI types in the training and validation cohorts. A predictive model was developed and validated using receiver operating characteristic (ROC) curve analysis. RESULTS: Multivariate analysis in the training cohort identified male sex (odds ratio [OR]: 3.33, 95% confidence interval [CI]: 1.57-7.06, p = 0.002), serum albumin levels (OR: 0.42, 95% CI: 0.19-0.91, p = 0.027), and serum alanine aminotransferase (ALT) levels (OR: 0.97, 95% CI: 0.94-0.99, p = 0.015) as significant predictors, along with ICI regimen types selected using the Akaike information criterion. The logistic regression model, expressed as p = 1/{1 + (-(5.02 + 1.20 × (sex [F:0, M:1])) - 0.87 × albumin [g/dL] - 0.03 × ALT [U/L] - 0.9 × (drug [non-anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) related regimen:0, anti-CTLA-4 related regimen:1]))}, achieved an area under the ROC (AUROC) of 0.73 (95% CI: 0.63-0.82) in the training cohort. At a cut-off of 0.86, the sensitivity was 60.3%, specificity 74.4%, positive predictive value 92.3%, and negative predictive value 26.9%. In the validation cohort, the AUROC was 0.752 (95% CI: 0.476-1.00). CONCLUSION: This predictive model demonstrates its utility in classifying ICI-LI types.


• Immunoscore Predicted by Dynamic Contrast-Enhanced Computed Tomography Can Be a Non-Invasive Biomarker for Immunotherapy Susceptibility of Hepatocellular Carcinoma.

  Eisuke Ueshima, Keitaro Sofue, Shohei Komatsu, Nobuaki Ishihara, Masato Komatsu, Akihiro Umeno, Kentaro Nishiuchi, Ryohei Kozuki, Takeru Yamaguchi, Takanori Matsuura, Toshifumi Tada, Takamichi Murakami

  Cancers, Mar. 2025, English, Background/Objectives: Although immunotherapy is the primary treatment option for intermediate-stage hepatocellular carcinoma (HCC), its efficacy varies. This study aimed to identify non-invasive imaging biomarkers predictive of the immunoscore linked to dynamic contrast-enhanced computed tomography (CECT). Methods: We performed immunohistochemical staining with CD3+ and CD8+ antibodies and counted the positive cells in the invasive margin (IM) and central tumor (CT), converting them to an immunoscore of 0 to 4 points. We assessed the dynamic CECT findings obtained from 96 patients who underwent hepatectomy for HCC and evaluated the relationship between dynamic CECT findings and immunoscores. For validation, we assessed the treatment effects on 81 nodules using the Response Evaluation Criteria in Solid Tumors in another cohort of 41 patients who received combined immunotherapy with atezolizumab and bevacizumab (n = 27) and durvalumab and tremelizumab (n = 14). Results: HCCs with peritumoral enhancement in the arterial phase (p < 0.001) and rim APHE (p = 0.009) were associated with the immunoscore in univariate linear regression analysis and peritumoral enhancement in the arterial phase (p = 0.004) in multivariate linear regression analysis. The time to nodular progression in HCCs with peritumoral enhancement in the arterial phase was significantly longer than that in HCCs without this feature (p < 0.001). Conclusions: We identified HCCs with peritumoral enhancement in the arterial phase as a noninvasive imaging biomarker to predict immune-inflamed HCC with a high immunoscore tendency. These HCCs were most likely to respond to combined immunotherapy.


• The potential efficacy of atezolizumab plus bevacizumab treatment for hepatocellular carcinoma patients with macroscopic portal vein tumor thrombus.

  Shohei Komatsu, Yoshihiko Yano, Kazuki Terashima, Yoshimi Fujishima, Jun Ishida, Nobuaki Ishihara, Takanori Matsuura, Tomoaki Okimoto, Yuzo Kodama, Takumi Fukumoto

  Surgery today, Feb. 2025, English, PURPOSE: The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) in the first-order or main trunk/contralateral branches (Vp3/4) is poor. The present study aimed to clarify the real-world data of atezolizumab plus bevacizumab treatment (Ate/bev) for HCC patients with Vp3/4 PVTT. METHODS: The subjects of this study were 22 consecutive HCC patients with Vp3/4 PVTT, who were treated with Ate/bev. Survival rates and radiological responses were evaluated based on the modified albumin-bilirubin (mALBI) grade [mALBI 1 + 2a (1/2a) versus 2b + 3 (2b/3)] using the modified Response Evaluation Criteria in Solid Tumors. RESULTS: The median survival time of the 22 patients was 15.0 months, with 1- and 2-year survival rates of 62.7% and 49.3%, respectively. The objective response (OR) rates of patients with mALBI 1/2a and 2b/3 were 91.7% (11/12) and 10.0% (1/10), respectively, with a significant difference (p < 0.001). The 2-year survival rates of patients with mALBI 1/2a and 2b/3 were 78.6% and 20.0%, respectively, with a significant difference (p = 0.0041). CONCLUSION: Ate/bev was effective for treating HCC patients with Vp3/4 PVTT. OR rate and MST were favorable, particularly for patients with preserved liver function (mALBI 1/2a), suggesting its great potential for the treatment of HCC in patients with Vp3/4 PVTT.


• Higher Absolute Lymphocyte Counts and Lower Des-γ-Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Combination Therapy for Hepatocellular Carcinoma.

  Yuta Inoue, Yoshihiko Yano, Saeko Kushida, Seiya Hirohata, Seitetsu Yoon, Eiichiro Yasutomi, Hirotaka Hirano, Soo Ki Kim, Ryutaro Yoshida, Yoshihide Ueda, Kenji Momose, Hiroki Hayashi, Takuo Kado, Katsuhisa Nishi, Hidenori Tanaka, Tomomitsu Matono, Atsushi Yamamoto, Hiroshi Tei, Chiharu Nishioka, Yosuke Yagi, Shoji Tamura, Tatsuya Sakane, Mayumi Ehara, Miki Kawano, Jun Kitadai, Takanori Matsuura, Yuuki Shiomi, Shohei Komatsu, Takumi Fukumoto, Toshifumi Tada, Yuzo Kodama

  JGH open : an open access journal of gastroenterology and hepatology, Feb. 2025, English, BACKGROUND AND AIMS: Tremelimumab plus durvalumab (Dur/Tre) combination therapy is now a first-line systemic therapy for advanced hepatocellular carcinoma (HCC). Because systemic therapy is not effective in some patients, it is clinically important to identify factors that could predict the response to treatment at an early stage. We investigated the factors associated with the response to Dur/Tre for advanced HCC in a clinical setting. METHODS: Seventy patients (median age 74 years; 61 men) who received Dur/Tre between March 2023 and September 2024 were analyzed. We examined the factors associated with the treatment response, including pretreatment factors and factors early in treatment. RESULTS: The median treatment duration was 77.5 (interquartile range [IQR] 28-187) days. The overall response and disease control rates were 25.8% and 58.1%, respectively. The median (IQR) progression-free survival (PFS) and overall survival (OS) were 82 (61-133) and 415 (337-NA) days, respectively. Multivariable analysis revealed that higher absolute lymphocyte count (ALC) and lower des-γ-carboxyprothrombin (DCP) levels were significantly associated with PFS. Receiver operating characteristic curve analysis showed that the cutoff value for ALC after 4 weeks of treatment in relation to clinical efficacy was 1125/mm3. A log-rank test using the Kaplan-Meier method showed that OS was significantly longer in patients with ALC above the cutoff and in patients whose DCP levels decreased after starting treatment. CONCLUSION: Higher ALC and lower DCP levels after treatment initiation were associated with the clinical efficacy of Dur/Tre for advanced HCC.


• Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.

  Nobuaki Ishihara, Shohei Komatsu, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Kentaro Tai, Keisuke Arai, Hiroaki Yanagimoto, Hirochika Toyama, Takanori Matsuura, Toshifumi Tada, Yuzo Kodama, Takumi Fukumoto

  Anticancer research, Jan. 2025, English, International Institute of Anticancer Research, BACKGROUND/AIM: Atezolizumab plus bevacizumab (AteBev) is widely used as a first-line treatment for advanced hepatocellular carcinoma (HCC). However, evidence regarding the optimal drug sequence following AteBev treatment is limited. This study aimed to compare the treatment outcomes between tyrosine kinase inhibitors (TKIs) and durvalumab plus tremelimumab (DurTre) following AteBev treatment. PATIENTS AND METHODS: Overall, 134 consecutive patients who received AteBev for advanced HCC were enrolled in this study. Treatment outcomes were retrospectively compared between TKIs (AteBev→TKI group) and DurTre (AteBev→DurTre group). RESULTS: The AteBev→TKI and Ate→DurTre groups included 46 and 7 patients, respectively. The AteBev→TKI group had significantly longer median progression-free survival after second-line treatment (3.6 vs. 0.94 months, p<0.001). The disease control rate was significantly higher in the AteBev→TKI group (p=0.020). The serum alpha-fetoprotein levels significantly decreased at one month in the AteBev→TKI group (0.909 vs. 1.435, p=0.035), whereas the albumin-bilirubin score significantly decreased at one month in the AteBev→TKI group (0.875 vs. 0.952, p=0.017). Each group reported no new unmanageable adverse events. CONCLUSION: TKIs may be a more optimal drug sequence than DurTre after AteBev treatment from an oncological perspective. TKIs following AteBev treatment require careful monitoring for deteriorating liver function.


• Diagnostic guide for immune checkpoint inhibitor-induced liver injury.

  Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru, Kazumichi Abe, Masanori Abe, Takanori Matsuura, Masataka Yokode, Masahiro Shiokawa, Yuzo Kodama, Mina Komuta, Kenichi Harada, Atsushi Tanaka

  Hepatology research : the official journal of the Japan Society of Hepatology, Aug. 2024, English, With the widespread use of immune checkpoint inhibitors (ICIs), liver injury (ICI-induced liver injury) as an immune-related adverse event has become a major concern in clinical practice. Because severe cases of liver injury require administration of corticosteroids, a comprehensive evaluation is crucial, including clinical course, blood and imaging tests, and if necessary, pathological examination through liver biopsy. As with liver injury induced by other drugs, classification of injury type by R-value is useful in deciding treatment strategies for ICI-induced liver injury. Histologically, the most representative feature is an acute hepatitis-like hepatocellular injury, characterized by diffuse lobular inflammation accompanied by CD8-positive T lymphocytes. Another condition that can cause liver injury during ICI treatment is cholangitis accompanied by non-obstructive bile duct dilatation and bile duct wall thickening. Many cases of ICI-induced cholangitis are classified as non-hepatocellular injury type, and they have been reported to respond poorly to corticosteroids. It is essential that gastroenterologists/hepatologists and doctors in various departments work in cooperation to develop a system that achieves early diagnosis and appropriate treatment of ICI-induced liver injury.


• Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy.

  Miki Kawano, Yoshihiko Yano, Atsushi Yamamoto, Eiichiro Yasutomi, Yuta Inoue, Jun Kitadai, Ryutaro Yoshida, Takanori Matsuura, Yuuki Shiomi, Yoshihide Ueda, Yuzo Kodama

  Diagnostics (Basel, Switzerland), Apr. 2024, English, Immune checkpoint inhibitor (ICI)-induced liver injury (LI) is a common adverse event, but the clinical characteristics based on the classification of hepatocellular injury and cholestatic types are not fully evaluated. This study aims to analyze risk factors and histological findings in relation to the classification of ICI-induced LI. In total, 254 ICI-induced LI patients among 1086 treated with ICIs between September 2014 and March 2022 were classified according to the diagnostic criteria for drug-induced LI (DILI), and their risk factors and outcomes were evaluated. Kaplan-Meier analyses showed that overall survival in patients with hepatocellular-injury-type LI was significantly longer than others (p < 0.05). Regarding pre-treatment factors, the lymphocyte count was significantly higher in patients with ICI-induced LI, especially in hepatocellular-injury-type LI. Gamma glutamyl transferase (γGTP) and alkaline phosphatase (ALP) were also significantly lower in patients with ICI-induced LI (p < 0.05). Multivariate analyses revealed that malignant melanoma, high lymphocyte count, and low ALP levels were extracted as factors contributing to hepatocellular-injury-type LI. The histological findings among 37 patients diagnosed as ICI-induced LI via liver biopsy also revealed that the spotty/focal necrosis was significantly frequent in hepatocellular-injury-type LI, whereas ductular reactions were frequently observed in cholestatic-type LI. It is suggested that the histological inflammation pattern in patients with LI is closely correlated with the type of DILI.


• Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen.

  Yoshihiko Yano, Itsuko Sato, Takamitsu Imanishi, Ryutaro Yoshida, Takanori Matsuura, Yoshihide Ueda, Yuzo Kodama

  Diagnostics (Basel, Switzerland), Mar. 2024, English, Currently, hepatitis B virus (HBV) core antibody (anti-HBc antibody) and HBV core-related antigen (HBcrAg) are widely used as serum markers for diagnosis based on the HBV core region. This review focused on anti-HBc antibodies and HBcrAg and aimed to summarize the clinical significance of currently used assay systems and the issues involved. While anti-HBc is very significant for clinical diagnosis, the clinical significance of quantitative assay of anti-HBc antibody has been reevaluated with improvements in diagnostic performance, including its association with clinical stage and prediction of carcinogenesis and reactivation. In addition, concerning the new HBcrAg, a high-sensitivity assay method has recently been established, and its diagnostic significance, including the prediction of reactivation, is being reevaluated. On the other hand, the quantitative level of anti-HBc antibody expressed in different units among assay systems complicates the interpretation of the results. However, it is difficult to standardize assay systems as they vary in advantages, and caution is needed in interpreting the assay results. In conclusion, with the development of highly sensitive HBcrAg and anti-HBc antibody, a rapid and sensitive detection assay system has been developed and used in clinical practice. In the future, it is hoped that a global standard will be created based on the many clinical findings.


• Histological diagnosis of polyploidy discriminates an aggressive subset of hepatocellular carcinomas with poor prognosis.

  Takanori Matsuura, Yoshihide Ueda, Yoshiyuki Harada, Kazuki Hayashi, Kisara Horisaka, Yoshihiko Yano, Shinichi So, Masahiro Kido, Takumi Fukumoto, Yuzo Kodama, Eiji Hara, Tomonori Matsumoto

  British journal of cancer, Oct. 2023, English, BACKGROUND: Although genome duplication, or polyploidization, is believed to drive cancer evolution and affect tumor features, its significance in hepatocellular carcinoma (HCC) is unclear. We aimed to determine the characteristics of polyploid HCCs by evaluating chromosome duplication and to discover surrogate markers to discriminate polyploid HCCs. METHODS: The ploidy in human HCC was assessed by fluorescence in situ hybridization for multiple chromosomes. Clinicopathological and expression features were compared between polyploid and near-diploid HCCs. Markers indicating polyploid HCC were explored by transcriptome analysis of cultured HCC cells. RESULTS: Polyploidy was detected in 36% (20/56) of HCCs and discriminated an aggressive subset of HCC that typically showed high serum alpha-fetoprotein, poor differentiation, and poor prognosis compared to near-diploid HCCs. Molecular subtyping revealed that polyploid HCCs highly expressed alpha-fetoprotein but did not necessarily show progenitor features. Histological examination revealed abundant polyploid giant cancer cells (PGCCs) with a distinct appearance and frequent macrotrabecular-massive architecture in polyploid HCCs. Notably, the abundance of PGCCs and overexpression of ubiquitin-conjugating enzymes 2C indicated polyploidy in HCC and efficiently predicted poor prognosis in combination. CONCLUSIONS: Histological diagnosis of polyploidy using surrogate markers discriminates an aggressive subset of HCC, apart from known HCC subgroups, and predict poor prognosis in HCC.


• A Case of Duodenal Edema-related Undiagnosed Hereditary Angioedema.

  Fumiaki Kawara, Takanori Matsuura, Kodai Yamanaka, Chiharu Nishioka

  Internal medicine (Tokyo, Japan), Aug. 2023, English


• Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma.

  Yoshihiko Yano, Atsushi Yamamoto, Takuya Mimura, Saeko Kushida, Seiya Hirohata, Seitetsu Yoon, Hirotaka Hirano, Soo Ki Kim, Yuri Hatazawa, Kenji Momose, Hiroki Hayashi, Takuo Kado, Katsuhisa Nishi, Hidenori Tanaka, Takanori Matsuura, Ryutaro Yoshida, Naoki Asaji, Eiichiro Yasutomi, Yuuki Shiomi, Akihiro Minami, Shohei Komatsu, Takumi Fukumoto, Yoshihide Ueda, Yuzo Kodama

  JGH open : an open access journal of gastroenterology and hepatology, Jul. 2023, English, BACKGROUND AND AIM: The purpose of this study was to analyze factors associated with the overall survival (OS) of atezolizumab/bevacizumab combination therapy for advanced hepatocellular carcinoma (aHCC). We also assessed the OS of patients with ineffective therapy and those who discontinued treatment owing to adverse events (AEs). METHODS: This retrospective multicenter study involved 139 patients with aHCC who received atezolizumab/bevacizumab combination therapy between November 2020 and September 2022. RESULTS: The median duration of treatment was 136.5 days, and the median observation period was 316 days. The overall response rate was 40%, and the disease control rate was 78% according to mRECIST criteria. Grade ≥2 AEs occurred in 63 patients (43%) and led to treatment discontinuation in 16 patients. Multivariate analysis revealed that treatment response and occurrence of grade ≥2 AEs after therapy, as well as low level of albumin-bilirubin (ALBI) grade and low level of des-gamma carboxy prothrombin (DCP) before therapy, were extracted as factors that contributed to OS. Log-rank tests with the Kaplan-Meier method showed significant differences in OS among these factors. The OS of patients who discontinued owing to AEs was significantly shorter than that of other patients. CONCLUSION: Not only factors before therapy but also treatment response and the appearance of AEs are involved in OS for atezolizumab/bevacizumab combination therapy. Although the development of AEs also contributed to OS, appropriate management of AEs is important to avoid discontinuing treatment with this combination.


• Endoscopic closure of cecal fistula using purse-string suture after plombage with polyglycolic acid sheets and fibrin glue.

  Fumiaki Kawara, Akihiro Minami, Kazuya Hara, Kodai Yamanaka, Takanori Matsuura, Mitsuko Mimura, Chiharu Nishioka

  Endoscopy, Nov. 2022, English


• Significance of post-progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma.

  Yoshihiko Yano, Atsushi Yamamoto, Akihiro Minami, Kenji Momose, Takuya Mimura, Soo Ki Kim, Hiroki Hayashi, Takuo Kado, Hirotaka Hirano, Seiya Hirohata, Seitetsu Yoon, Katsuhisa Nishi, Hiroshi Tei, Hidenori Tanaka, Sachiko Oouchi, Takanori Matsuura, Eiichiro Yasutomi, Yuri Hatazawa, Yuuki Shiomi, Yoshihide Ueda, Yuzo Kodama

  JGH open : an open access journal of gastroenterology and hepatology, Jun. 2022, English, BACKGROUND AND AIM: Molecular-targeted therapies such as sorafenib and lenvatinib have long been used as first-line treatment for advanced hepatocellular carcinoma (aHCC). However, adverse events or limited therapeutic effects may necessitate the change to another therapeutic option, known as post-progression therapy. To investigate the significance of post-progression therapy, we analyzed the outcomes of aHCC patients following first-line molecular-targeted therapy in a real-world study. METHODS: This retrospective, multicenter study involved patients with aHCC who received sorafenib or lenvatinib as first-line therapy between January 2011 and September 2021. RESULTS: In total, 513 patients were analyzed: 309 treated with sorafenib and 204 with lenvatinib. The overall response and disease control rates were 15 and 50%, respectively, in the sorafenib group and 30 and 75%, respectively, in the lenvatinib group (P < 0.001). Kaplan-Meier analysis revealed no significant differences in progression-free survival and overall survival (OS) between the two treatments. Multivariate analysis revealed that fibrosis-4 index, disease control rate, post-progression therapy, and use of an immune checkpoint inhibitor (ICI) were significantly associated with OS. OS was significantly longer in patients who received post-progression therapy than in those who did not (log-rank P < 0.001). Most patients who received an ICI as post-progression therapy had previously received lenvatinib. Among lenvatinib-treated patients, OS was significantly longer in patients who received an ICI than in patients received another or no post-progression therapy (P = 0.004). CONCLUSION: The introduction of newer drugs for post-progression therapy is expected to prolong survival. ICI-based regimens appear to be effective after lenvatinib.

• 消化器指定難病と免疫関連有害事象に共通する自己免疫機構の解明およびその臨床応用

  児玉 裕三, 渡邉 大輔, 増田 充弘, 松浦 敬憲

  日本学術振興会, 科学研究費助成事業, 基盤研究(B), 神戸大学, 01 Apr. 2025 - 31 Mar. 2028


• 癌細胞の多倍体化に着目した、肝内胆管癌の予後不良バイオマーカーの探索

  松浦 敬憲

  日本学術振興会, 科学研究費助成事業, 若手研究, 神戸大学, 01 Apr. 2025 - 31 Mar. 2028